bims-carter Biomed News
on CAR-T Therapies
Issue of 2026–11–15
eighty-one papers selected by
Luca Bolliger, lxBio



  1. Ann Hematol. 2026 Aug 15. pii: 510. [Epub ahead of print]105(12):
      Adoptive cellular immunotherapy has transformed the treatment landscape for hematologic malignancies; however, its broader application to solid tumors remains limited by antigen heterogeneity, inadequate persistence, restricted tumor infiltration, and the profoundly immunosuppressive tumor microenvironment (TME). While conventional CAR-T cell therapy has demonstrated remarkable clinical success, no single immune-cell platform is likely to overcome all biological barriers encountered in complex solid tumors. Emerging evidence instead supports a shift toward an integrated cellular immunotherapy ecosystem that combines the complementary strengths of multiple engineered immune cell populations. In this review, we present a unifying framework for the multi-layered engineering of next-generation immune cell therapies, encompassing CAR-natural killer (CAR-NK) cells, TCR-engineered αβ T cells, γδ T cells, CAR-natural killer T (CAR-NKT) cells, and CAR-macrophages. Rather than considering these platforms as isolated technologies, we examine how shared engineering strategies, including cytokine armoring, CRISPR-based genome editing, protein-level receptor optimization, tumor-responsive gene circuits, metabolic reprogramming, and induced pluripotent stem cell (iPSC)-based manufacturing, can be integrated to enhance persistence, functionality, safety, and resistance to TME-mediated suppression. We further discuss the biological rationale, preclinical advances, and emerging clinical evidence supporting each platform, highlighting their distinct and complementary mechanisms of tumor recognition and immune activation. Finally, we propose that the future of cancer immunotherapy lies not in the optimization of a single cellular modality, but in the development of synergistic, scalable, and off-the-shelf engineered immune-cell networks capable of delivering durable and effective responses against heterogeneous solid tumors.
    Keywords:  CAR-NK; CAR-NKT; CAR-macrophages; Cellular immunotherapy; Cytokine armoring; Gamma-delta T cells; TCR-engineered T cells
    DOI:  https://doi.org/10.1007/s00277-026-07243-2
  2. Cells. 2026 Oct 25. pii: 1938. [Epub ahead of print]15(21):
      Adoptive T-cell therapy has demonstrated substantial clinical efficacy in several hematological malignancies, but autologous manufacturing remains limited by variability in starting cell material, manufacturing time, product heterogeneity, and T-cell dysfunction. Induced pluripotent stem cells (iPSCs) provide a potentially scalable and genetically engineerable source for the generation of standardized allogeneic T-cell products. This review summarizes current approaches to the differentiation of iPSCs into distinct T-cell phenotypes and evaluates their potential for cancer immunotherapy. We first discuss iPSC-derived conventional αβ T cells, including recent advances in feeder-free and scalable differentiation, maturation, and genetic engineering, as well as preclinical and early clinical evidence. We then examine γδ T cells, invariant natural killer T cells, and mucosal-associated invariant T cells, focusing on their distinctive antigen-recognition mechanisms, effector functions, tissue tropism, differentiation strategies, and therapeutic applications. Across these populations, iPSC technology may facilitate standardized and scalable production while enabling targeted engineering of T-cell specificity and functional properties. However, important challenges remain, including efficient lineage-specific differentiation, maturation, phenotypic consistency, long-term persistence, tumor infiltration, and control of alloreactivity and immunogenicity. Overall, iPSC-derived T cells represent a versatile platform for developing diverse cellular immunotherapies, although their clinical potential remains dependent on further technological and translational advances.
    Keywords:  T cell phenotypes; adoptive cell therapy; induced pluripotent stem cell
    DOI:  https://doi.org/10.3390/cells15211938
  3. Front Immunol. 2026 ;17 1866170
      Chimeric antigen receptor-engineered natural killer (CAR-NK) cell therapy has emerged as a promising cancer treatment by combining the antigen specificity of CAR engineering with the intrinsic cytotoxicity of NK cells. Compared with CAR-T cell therapy, CAR-NK cells exhibit a lower risk of graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and immune-related toxicities while offering the potential for allogeneic "off-the-shelf" applications. Nevertheless, their therapeutic efficacy remains limited by insufficient persistence, poor trafficking, and the immunosuppressive tumor microenvironment (TME). Extracellular vesicles (EVs), particularly small EVs (sEVs) derived from CAR-NK cells may retain tumor-targeting features and cytotoxic cargo of their parental cells while offering potential advantages of a cell-free format, including reduced proliferative risk, improved tissue penetration, enhanced biological stability, and the capacity to deliver therapeutic proteins, nucleic acids, and small molecules. Emerging preclinical evidence demonstrates that CAR-NK-derived sEVs can directly eliminate tumor cells while simultaneously modulating the TME, making them an attractive cell-free immunotherapeutic platform; however, their safety and pharmacological properties require dedicated validation. Despite their considerable promise, several challenges remain, including scalable manufacturing, standardized characterization, vesicle heterogeneity, cargo loading efficiency, biodistribution, and pharmacokinetic optimization. This review summarizes recent advances in CAR-NK-derived sEV research, critically discusses their biological properties, engineering strategies, preclinical evidence, translational challenges, and future clinical prospects, highlighting their emerging role at the intersection of cancer immunotherapy and nanomedicine.
    Keywords:  CAR-NK cell; CAR-NK-derived EVs; cancer immunotherapy (CIT); exosome; nanomedicine
    DOI:  https://doi.org/10.3389/fimmu.2026.1866170
  4. Mol Ther Oncol. 2026 Dec 17. 34(4): 201363
      Chimeric antigen receptor (CAR) T cell therapy represents an advancement in the treatment of hematologic malignancies, offering remissions in relapsed or refractory disease. However, its global implementation is limited by high production costs, logistical complexity, and the need for specialized facilities that comply with biosafety and regulatory standards. In Brazil, all CAR-T products are imported, leading to high costs and delays in patient access. To overcome these barriers, academic institutions have established local CAR-T manufacturing platforms. This review provides an overview of the scientific, technical, and regulatory aspects of academic CAR-T development in Brazil, highlighting key advances and challenges. We discuss cell sources, gene-transfer systems, manufacturing strategies, quality control (QC), and regulatory frameworks. Efforts from institutions such as Hospital Israelita Albert Einstein, University of São Paulo (USP), Butantan Institute, National Cancer Institute (INCA), and Oswaldo Cruz Foundation (Fiocruz) demonstrate complementary approaches. These initiatives underscore the feasibility of developing CAR-T therapies in low- and middle-income countries through innovation, technology transfer, and financing. Finally, we address the integration of CAR-T therapy into the Brazilian public health system, emphasizing workforce training, clinical logistics, and cost-effectiveness to ensure access. Overall, the Brazilian experience illustrates how academic collaboration can translate research into clinical application.
    Keywords:  Brazil; CAR-T cell therapy; academic development; cell manufacturing; hematologic malignancies
    DOI:  https://doi.org/10.1016/j.omton.2026.201363
  5. Int J Nanomedicine. 2026 ;21 651751
      Lung cancer remains a major therapeutic challenge because of its molecular and antigenic heterogeneity, rapid evolution, treatment resistance, and immunosuppressive tumor microenvironment (TME). Although chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment of hematological malignancies, its efficacy in lung cancer remains constrained by antigen heterogeneity, poor tumor trafficking and infiltration, T-cell dysfunction, suppressive stromal and myeloid compartments, manufacturing complexity, and pulmonary on-target off-tumor toxicity. Nanomedicine offers a versatile platform to address these barriers by improving CAR-T manufacturing and functional fitness, enabling targeted delivery of nucleic acids and immunomodulators, remodeling the TME, enhancing local accumulation and controlled activation, and supporting transient in situ generation of CAR-engineered immune cells. This review integrates these advances within a Route-Antigen-Microenvironment-Programming (RAMP) framework and emphasizes the mechanistic interdependence among delivery route, target selection, local tumor ecology, and CAR generation and control. We examine the antigen landscapes of non-small-cell and small-cell lung cancer and propose a quantitative framework for antigen selection that incorporates antigen density, spatial and temporal heterogeneity, normal-tissue safety, and engineering compensability. We further discuss nanotechnology-assisted manufacturing, cell-surface nanobackpacks, tumor preconditioning, local biomaterial reservoirs, in vivo CAR programming, pulmonary delivery, multimodal therapy, and theranostic monitoring. Most nano-enabled approaches are still supported primarily by preclinical studies or evidence from non-lung-cancer settings, underscoring the need for standardized assessment of biodistribution, reproducibility, immunogenicity, pulmonary safety, and long-term material fate. Integrating quantitative antigen profiling with biodegradable and controllable materials and lung-relevant translational models may help advance CAR-engineered immunotherapy toward a spatially controlled, dynamically monitored, and personalized therapeutic platform for lung cancer.
    Keywords:  CAR-T cell therapy; in situ CAR programming; lung cancer; nanomedicine; precision immunotherapy; pulmonary delivery
    DOI:  https://doi.org/10.2147/IJN.S651751
  6. Int J Hematol. 2026 Nov 13.
      Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable success in treating B-cell malignancies and multiple myeloma. However, CAR-T therapy for acute myeloid leukemia (AML) remains challenging. Key issues include the lack of a tumor-specific target antigen, antigen expression heterogeneity, on-target off-tumor toxicity, and limitations of individualized manufacturing of autologous cell therapies. Recent strategies include optimized antigen recognition, multi-antigen targeting, and use of donor-recipient HLA mismatch following allogeneic hematopoietic cell transplantation. Additionally, off-the-shelf cell therapies including CAR NK cells are being developed. Furthermore, in vivo CAR T-cell generation has emerged as a distinct approach that may eliminate the need for ex vivo manufacturing. This review discusses these strategies and explores how optimizing target selection, the effector cell platform, and manufacturing processes could expand CAR-based cellular therapy.
    Keywords:  AML; CAR-NK; CAR-T therapy
    DOI:  https://doi.org/10.1007/s12185-026-04318-8
  7. Transplant Cell Ther. 2026 Nov 12. pii: S2666-6367(26)00894-8. [Epub ahead of print]
      Engineering immune cells, particularly T lymphocytes, with chimeric antigen receptors (CARs) has become one of the most successful modalities of cancer immunotherapy, as evidenced by the approval and clinical use of multiple CAR-T cell products. Current CAR platforms predominantly rely on monoclonal antibody-derived single-chain variable fragments (scFvs) for target recognition. While scFv-based CARs have achieved remarkable clinical successes, they also exhibit notable limitations, including the potential to elicit anti-CAR immune responses, tonic signaling that contributes to CAR-T cell exhaustion, tumor escape via antigen loss or downregulation, and on-target, off-tumor toxicities. In response, researchers have explored alternative binding moieties for CAR architectures. Natural ligands and receptors represent one such class of alternatives. These approaches may offer advantages over conventional scFv-based CARs, such as potentially lower immunogenicity with fully human-derived domains, the ability to engage multiple targets or ligands, access to antigens that are challenging for scFvs, and the use of protein-protein interfaces shaped by evolution within human physiology. However, these benefits are not absolute. CAR junctions, non-native orientations, expression levels, modifications, and the cellular context can still generate immunogenic epitopes or dysfunctional products. Additionally, natural ligand/receptor pairs may transmit unwanted agonistic or regulatory signals that require careful engineering to mitigate. This review discusses recent advances in ligand/receptor-based CARs from a translational perspective. It also provides a critical overview of their inherent limitations, alongside potential solutions to support the rational design of next-generation constructs.
    Keywords:  CAR-T cell therapy; Chimeric antigen receptor; Ligand-based CAR; Receptor-based CAR; Translational immunotherapy
    DOI:  https://doi.org/10.1016/j.jtct.2026.11.026
  8. Exp Hematol Oncol. 2026 Nov 12. pii: 125. [Epub ahead of print]15(1):
      Over the past decade, chimeric antigen receptor (CAR) T-cell therapy has achieved durable remissions in patients with relapsed or refractory haematological malignancies. However, its broader clinical adoption remains constrained by patient-specific ex vivo manufacturing, substantial treatment-related toxicities and limited efficacy in solid tumours. In vivo CAR immunotherapy enables endogenous immune cells to be genetically reprogrammed directly within the body, bypassing leukapheresis, ex vivo expansion and individualized cell manufacturing. This Review focuses specifically on in vivo CAR immune cell engineering for cancer therapy, encompassing haematological malignancies and solid tumours; applications in non-malignant diseases, including autoimmune disorders, are outside its scope. We examine emerging technologies for generating CAR immune cells in vivo and discuss how viral vectors, non-viral nanocarriers and biomimetic delivery systems could improve the precision, scalability and controllability of cancer immunotherapy. We further highlight immune effectors beyond CAR T cells, including CAR macrophages and CAR natural killer cells, whose distinct cytotoxic, phagocytic and immunomodulatory functions may offer complementary approaches to treating solid tumours. We discuss strategies involving tumour-microenvironment remodelling, metabolic adaptation and precision genome engineering to improve immune-cell persistence, mitigate functional exhaustion, enhance tumour infiltration and limit antigen escape. Emerging clinical studies in haematological malignancies provide initial proof of concept that functional CAR cells can be generated in patients, although long-term safety, durability and reproducibility remain to be established. A central challenge is to generate these cells with sufficient cellular and spatial precision while maintaining control over their activity over time. We discuss how cell-subset-specific delivery, programmable CAR circuits, multicellular engineering, intelligent biomaterials and artificial intelligence could support the development of in vivo CAR immunotherapy as a scalable, controllable and potentially repeatable cancer treatment.
    Keywords:  CAR T cells; Cancer immunotherapy; Immune-cell engineering; In vivo CAR; Targeted delivery
    DOI:  https://doi.org/10.1186/s40164-026-00858-1
  9. Front Immunol. 2026 ;17 1931185
      Immune-mediated inflammatory diseases (IMIDs) remain treatment-dependent in many patients with severe, refractory, or organ-threatening disease. Deep B-cell depletion using chimeric antigen receptor (CAR)-based therapies may induce clinical improvement and measurable immune reconstitution, but conventional autologous CAR-T manufacturing limits speed, standardization, and access. This structured narrative review compares allogeneic CAR-T, allogeneic CAR-natural killer (CAR-NK), and in vivo CAR-T. Bibliographic databases, trial registries, conference repositories, reference lists, and traceable sponsor, media, and regulatory sources were searched through 3 September 2026. Allogeneic CAR-T has the broadest clinical evidence base, although cohorts are small and mostly early-phase. All CAR-NK products with reported IMID clinical data are allogeneic; available studies suggest transient kinetics, repeat-infusion feasibility, and encouraging short-term tolerability, but durability is uncertain. Peer-reviewed in vivo evidence now includes a five-patient non-integrating LNP/linear mRNA report and a 16-patient integrating lentiviral report. Both are early, uncontrolled studies and neither supports class-wide inference. Disease-specific outcomes, background treatment, follow-up, and assays differ markedly. Complete treatment-free remission was distinguished from glucocorticoid withdrawal, immunosuppressant reduction, and remission on permitted therapy. CAR-cell, transgene DNA, and RNA detection were not pooled, and peripheral blood B-cell depletion was not treated as proof of tissue depletion. Naive-dominant B-cell recovery and declining autoantibodies indicate immune remodeling, not restored tolerance. No indirect efficacy ranking is justified. Prospective studies need standardized disease endpoints, treatment-free remission definitions, analyte-specific pharmacokinetics, paired blood-tissue pharmacodynamics, and long-term genomic, immune, and safety surveillance.
    Keywords:  B-cell depletion; allogeneic CAR-NK; allogeneic CAR-T; immune reconstitution; immune-mediated inflammatory diseases; in vivo CAR-T
    DOI:  https://doi.org/10.3389/fimmu.2026.1931185
  10. Int J Mol Sci. 2026 Oct 27. pii: 9587. [Epub ahead of print]27(21):
      Chimeric antigen receptor T (CAR-T) cell therapy has completely reshaped the therapeutic landscape for some blood cancers, including B-cell lymphoma, myeloma, and acute lymphoblastic leukemia. However, the complications associated with this powerful therapy are preventing it from being used more widely. This review explores the underlying biology, clinical signs, and current treatments for the three major early CAR-T cell therapy-associated toxicities: cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Here, we outline key findings from preclinical animal models, data from multicenter clinical trials, and real-world patient cohort study data to delineate how infused cells and different host-derived and blood-brain barrier disruptions contribute to these adverse effects. A growing body of evidence is revealing that the patient's own monocytes and macrophages, not just the infused CAR-T cells, may contribute to driving systemic toxicities primarily by releasing interleukin-1 (IL-1) and IL-6. A more thorough and mechanistically detailed understanding of CAR-T cell therapy-associated toxicity is needed to develop better predictive tools and treatment strategies so that patients derive the greatest antitumor benefits with the lowest risk of severe treatment-related complications.
    Keywords:  CAR-T cell therapy; anakinra; cytokine release syndrome; immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome; immune effector cell-associated neurotoxicity syndrome; macrophage activation; neuroinflammation; predictive biomarkers; tocilizumab
    DOI:  https://doi.org/10.3390/ijms27219587
  11. Immune Netw. 2026 Oct;26(5): e40
      Engineered T cell therapies have transformed cancer immunotherapy, yet their application to solid tumors remains limited by Ag heterogeneity, shared Ag expression in normal tissues, immunosuppressive tumor microenvironments, and immune-mediated toxicities. These barriers indicate that improving cytotoxic potency alone is insufficient. Instead, therapeutic precision depends on how engineered T cells interpret antigenic and immunological context. We discuss solid tumor Ag biology as a determinant of receptor selection, therapeutic efficacy, and on-target off-tumor toxicity. We then examine chimeric Ag receptor, TCR-based, TCR-mimic, soluble TCR, T cell Ag couplers, TCR fusion constructs, and synthetic TCR and Ag receptor/HLA-independent TCR (STAR/HIT) systems with emphasis on Ag accessibility and signaling architecture. We further summarize toxicity mechanisms, including systemic inflammatory amplification, Ag distribution-dependent tissue injury, TCR cross-reactivity, and receptor-associated signaling dysregulation. Finally, we review programmable strategies, including logic-gated receptors, synthetic Notch circuits, quantitative Ag sensing, adaptor-controlled receptors, and genome editing, as approaches for spatial, temporal, and quantitative control. This Ag-guided framework provides a structured basis for matching Ag biology with receptor architecture and safety-control strategies, while emphasizing the need for careful translational evaluation in solid tumor T cell therapy.
    Keywords:  Gene editing; Immunotherapy, adoptive; On-target off-tumor toxicity; Receptors, antigen, T-cell; Solid tumors; Synthetic receptors
    DOI:  https://doi.org/10.4110/in.2026.26.e40
  12. Front Immunol. 2026 ;17 1939952
       Background: CAR/TCR-engineered cellular therapies are increasingly investigated in musculoskeletal sarcomas, but the clinical development portfolio spans heterogeneous histologies, platforms, antigens, and basket protocols. We mapped the TrialTrove-derived landscape while explicitly separating engineered-receptor products from other cell-based immunotherapies.
    Methods: TrialTrove clinical trial data were retrieved on 10 June 2026 and constituted the sole data source. Candidate records were identified using prespecified musculoskeletal-sarcoma disease terms and CAR/TCR-engineered-cell product terms. Two investigators independently assessed eligibility and assigned standardized classifications, with disagreements adjudicated by a third investigator. Potential duplicate representations were evaluated using TrialTrove, NCT, and normalized secondary identifiers plus study-level characteristics. We summarized temporal, geographic, phase, status, sponsor, protocol-planned enrollment, platform, target, disease-scope, co-intervention, concentration, and field-availability characteristics. Broader solid-tumor records with explicit sarcoma eligibility were reported separately, the export did not permit consistent determination of actual sarcoma enrollment or a dedicated sarcoma cohort.
    Results: Of 140 identified records, 121 were eligible: 38 (31.4%) were sarcoma-specific and 83 (68.6%) were broader solid-tumour records with explicit sarcoma eligibility. Among 110 records with a start year, 63 (57.3%) began during 2021-2026. Phase I or I/II accounted for 108/121 records (89.3%), and median protocol-planned enrollment was 24 participants (IQR 15-49, n=103). The United States and China contributed 55.2% of 163 trial-country links. TCR-T and CAR-T accounted for 60 (49.6%) and 52 (43.0%) records, respectively. NY-ESO-1 contributed 45/125 trial-target links (36.0%), after excluding 12 Unspecified reporting links, the three most frequent specified antigens contributed 66/113 specified-antigen links (58.4%).
    Conclusions: Engineered cellular-therapy development in musculoskeletal sarcomas has accelerated but remains predominantly early phase, geographically and antigenically concentrated, and represented largely by broader solid-tumour protocols that list sarcoma eligibility. Prespecified sarcoma strata, dedicated and independently analyzable cohorts, biomarker enrichment, harmonized outcomes, and transparent adjunct-strategy reporting should strengthen future evidence generation. This TrialTrove-based record analysis does not establish actual sarcoma enrollment in basket protocols, comparative efficacy, clinical superiority of a platform or antigen, or exhaustive global coverage.
    Keywords:  TCR-T; TrialTrove; basket trial; car-t; clinical trial landscape; engineered cellular therapy; musculoskeletal sarcoma
    DOI:  https://doi.org/10.3389/fimmu.2026.1939952
  13. Semin Neurol. 2026 Nov 12.
       Abstract: Advances in cancer immunotherapy have transformed survival outcomes and driven widespread adoption of these treatments. However, as the population receiving immunotherapy has grown, neurologic complications have increasingly emerged, with rates of 1 to 3% among patients receiving immune checkpoint inhibitors and 26.9% among chimeric antigen receptor (CAR) T cell therapy recipients across all FDA-approved products. This review focuses on the early recognition and acute management of neurologic toxicities associated with immunotherapy, with particular emphasis on immune effector cell-associated neurotoxicity syndrome (ICANS) related to CD19 and BCMA-directed CAR T cell therapies. Herein we synthesize current understanding of clinical phenotypes and risk factors for severe neurotoxicity, and review evidence-based approaches to diagnostic evaluation, including neuroimaging, electroencephalography, and laboratory markers. Practical management strategies for severe cases are discussed, including corticosteroid initiation, cytokine-directed immunomodulatory therapies, exploratory therapies, and neurocritical supportive care for fulminant cerebral edema and status epilepticus. We address less common but high-risk neurologic complications associated with CAR T cell therapy beyond ICANS. Lastly, we touch upon key clinical findings and treatments for acute neurologic complications related to immune checkpoint inhibitors, bispecific T cell engagers, tumor-infiltrating lymphocyte therapy, and engineered T cell receptor therapies.
    DOI:  https://doi.org/10.1055/a-2979-8424
  14. Transplant Cell Ther. 2026 Nov 11. pii: S2666-6367(26)00876-6. [Epub ahead of print]
      Chimeric antigen receptor (CAR) T-cell therapy has transformed treatment of hematologic malignancies, yet access remains limited by geographic, referral, infrastructure, and treatment-center capacity barriers. Expanding CAR T-cell therapy into community oncology settings offers an opportunity to increase capacity and provide treatment closer to where patients live. Drawing on the experience of a community-based transplant and cellular therapy network, we propose a practical framework for establishing community-based CAR T-cell therapy programs. Program development should begin with market and gap assessments to define patient need, existing capabilities, infrastructure requirements, and financial sustainability. Foundational elements include multidisciplinary clinical and administrative leadership, trained personnel, appropriate outpatient and infusion space, and solutions for apheresis, product storage, and logistics. Standardized clinical pathways, staff training, electronic health record-enabled workflows, and operating procedures are essential for patient selection, treatment delivery, toxicity management, and care coordination. Outpatient care requires structured monitoring, rapid escalation pathways, and an engaged hospital partner for emergency and inpatient management of complications. Programs must also establish capabilities for payer and manufacturer contracting, revenue-cycle management, regulatory requirements, and management of out-of-specification products. Robust quality systems and continuous quality improvement are fundamental to developing safe, sustainable, high-quality community CAR T-cell programs.
    Keywords:  CAR T-cell; Cellular therapy; Community oncology; Immune effector cell therapy; Quality of care
    DOI:  https://doi.org/10.1016/j.jtct.2026.11.005
  15. Mult Scler Relat Disord. 2026 Nov 10. pii: S2211-0348(26)01085-0. [Epub ahead of print]117 108050
      Multiple sclerosis (MS) combines peripheral immune dysregulation, compartmentalized central nervous system inflammation, and neurodegeneration. This critical narrative review evaluates the rationale, clinical evidence, safety, biomarkers, and development of chimeric antigen receptor (CAR) T-cell therapy in MS. Early studies demonstrate peripheral B-lineage depletion, CAR T-cell detection in cerebrospinal fluid, and changes in intrathecal biomarkers. They do not directly demonstrate depletion of meningeal or parenchymal B cells, durable clinical efficacy, or restored immune tolerance. A durable immune reset remains unproven. Deeper depletion does not establish superiority to anti-CD20 therapy; in one spontaneous experimental autoimmune encephalomyelitis model, meningeal B-cell depletion accompanied increased demyelination and axonal injury. Experience in other autoimmune diseases supports feasibility but cannot establish benefit in progressive MS. A preliminary October 2026 sponsor report from 66 Breakfree-2 participants with MS described cytokine release syndrome in 42.4% and five neurotoxicity cases, including one resolved grade 4 event. A post-cutoff death from septic pneumonia occurred after treatment for delayed motor symptoms, including high-dose cyclophosphamide; causation cannot be isolated from this report. Cytopenias, infections, hypogammaglobulinemia, and uncertain long-term immune effects also require surveillance. In vivo CAR generation could simplify manufacturing but raises unresolved questions about delivery specificity, persistence, and safety. Controlled trials must distinguish target engagement from sustained disability benefit using standardized clinical, imaging, biomarker, and patient-reported outcomes. CAR-T therapy remains investigational in MS; its role depends on durable benefit, acceptable toxicity, and comparative evidence against established therapies.
    Keywords:  B-cell depletion; Biomarkers; CAR T-cells; Cellular therapy; Multiple sclerosis; Neuroimmunology; Progressive multiple sclerosis
    DOI:  https://doi.org/10.1016/j.msard.2026.108050
  16. Front Immunol. 2026 ;17 1934301
      Despite recent advances in the field, Chimeric Antigen Receptor T (CAR-T) cell toxicities remain a significant burden throughout both the early and late post-infusion periods, affecting patient outcomes and complicating clinical management. Several risk factors for these side effects have been identified and multiple predictive scores and models have been developed, focusing mainly on clinical and inflammatory parameters assessed before or after CAR-T cell infusion. However, the majority of these scores have been derived and validated in retrospective cohorts, with external validation available only for a few of them predicting only CRS, ICANS or ICAHT risk. Several newly described toxicities still lack any predictive tool, and even the existing scores for CRS and ICANS have not yet been validated across all CAR-T disease indications, limiting their generalizability. The CAR-HEMATOTOX (CAR-HT), initially developed for ICAHT risk prediction, remains the most extensively validated tool to date. Despite this, no predictive model has yet been prospectively validated within interventional trials randomizing patients according to predicted risk. This minireview aims to provide an up-to-date overview of currently validated toxicity prediction scores in CAR-T cell therapy, along with prediction tools under development, future research directions and their potential integration into routine clinical practice to guide risk-adapted patient management.
    Keywords:  CAR-T cell therapy; CRS; ICAHT; ICANS; prediction
    DOI:  https://doi.org/10.3389/fimmu.2026.1934301
  17. Cytotherapy. 2026 Sep 09. pii: S1465-3249(26)00968-0. [Epub ahead of print]29(1): 103008
      Efficient ex vivo activation is a critical determinant of T-cell expansion, engineering efficiency and functional programming in adoptive cell therapy manufacturing. Current activation platforms predominantly rely on nanoscale or magnetic particles that may undergo phagocytic uptake, require complex removal procedures and contribute to variability in monocyte-containing cultures. Here, we describe Atract T-Cell Activation Kit, a large-particle (40 μm) T-cell activation system designed to provide robust stimulation while simplifying downstream handling. Atract particles were not internalized by phagocytic cells in peripheral blood mononuclear cell up to 24 h, whereas 4.5 μm Dynabeads were internalized from 2 h onward. After size-based filtration, no residual particle was detected in 8 of 10 runs and never more than one, corresponding to 99.99997% removal. Benchmarked against TransAct, the activation reagent most widely used in clinical chimeric antigen receptor (CAR)-T manufacturing, Atract induced comparable activation, proliferation, viability and lentiviral transduction efficiencies while enriching for CD8⁺ T cells and preserving less differentiated memory-associated subsets. In CAR-T manufacturing workflows, Atract-activated cells showed higher cytotoxic activity against CD19⁺ targets than TransAct-activated cells, with lower secretion of selected pro-inflammatory cytokines and sustained granzyme B production following antigen engagement. Activation and expansion scaled across multiple G-Rex culture formats, supporting compatibility with translational manufacturing. Collectively, these findings indicate that activation particle architecture influences T-cell phenotype, functional programming and manufacturability. Atract represents a scalable activation platform that combines efficient T-cell stimulation with quantifiable clearance from the final product, resistance to phagocytic uptake and distinct CAR-T functional properties relevant to engineered cell therapy production.
    Keywords:  CAR T manufacturing; T-cell activation; cell therapy manufacturing; phagocytic uptake; translational immunotherapy
    DOI:  https://doi.org/10.1016/j.jcyt.2026.103008
  18. Front Immunol. 2026 ;17 2002535
      The T-cell receptor (TCR) is the central mediator of antigen-specific recognition and a key regulator of T-lymphocyte function. Current evidence indicates that TCR signaling is not a linear cascade but a multilevel dynamic system in which cellular responses are shaped by the combined effects of TCR-CD3 structural organization, spatial receptor distribution, the lipid microenvironment, mechanical forces, kinase and phosphatase activity, co-stimulatory and inhibitory receptors, cellular metabolic state, and the strength and duration of TCR interactions with peptide-MHC (pMHC) complexes. This review summarizes current concepts of the molecular and spatial organization of TCR-CD3; mechanisms of signal initiation involving Lck, CD45, SHP phosphatases, ITAMs, ZAP-70, and the LAT-SLP-76 signalosome; and the coupling of TCR signaling to T-cell metabolic programs. Particular attention is paid to the nonlinear relationship between functional responses, TCR affinity, and target pMHC density; the role of chronic antigenic stimulation in T-cell exhaustion and activation-induced cell death (AICD); and the involvement of NFAT-, TOX-, NR4A-, and TCF1-dependent programs in this process. We also discuss the translational relevance of these mechanisms to antitumor immunotherapy and the restoration of immune tolerance, including immune checkpoint blockade, CAR-T, TCR-T, and TCR-Treg approaches and CD3/TCR-directed T-cell-engager platforms. Finally, we consider the concept of TCR signal tuning, according to which therapeutic efficacy is determined not by maximal receptor signal strength but by an optimal balance between antigen sensitivity, specificity, effector activity, metabolic fitness, and the ability of T cells to retain function under sustained antigenic pressure.
    Keywords:  T cell receptor; T-cell exhaustion; TCR signaling; TCR-T cells; functional avidity; immunometabolism; pMHC density; signal transduction
    DOI:  https://doi.org/10.3389/fimmu.2026.2002535
  19. Sci Adv. 2026 Nov 13. 12(46): eaej2663
      PRGN-3008 is a CD19 CAR T cell designed to overcome key limitations in ex vivo and in vivo CAR T manufacturing, cost, safety, and therapeutic durability. Featuring decentralized overnight manufacturing without ex vivo expansion, PRGN-3008 is engineered using a single nonviral transposon to encode CD19 CAR, membrane-bound interleukin-15 (mbIL-15) for improved persistence, PD-1-targeting microRNAs to prevent exhaustion, and an inducible safety switch for controlled in vivo elimination. Safety studies showed low vector copy numbers, favorable integration profile, and efficient CAR T ablation upon safety-switch activation. The combined mbIL-15 expression and PD-1 down-regulation preserved PRGN-3008 polyfunctionality and sustained cytotoxicity across repeated tumor challenges, outperforming nonarmored or singly modified CAR T cells. In xenograft models, overnight-manufactured PRGN-3008 without ex vivo expansion and activation achieved durable tumor clearance, prolonged tumor-free survival, robust antigen dependent expansion, and enrichment of memory T cell phenotypes linked to clinical durability. Notably, PRGN-3008 generated from heavily pretreated patients with systemic lupus erythematosus or lupus nephritis, maintained effector function, resisted terminal differentiation under chronic antigen exposure, and effectively depleted autoreactive B cells in a humanized mouse model. Transcriptomic analysis revealed that the combination of mbIL-15 expression and PD-1 down-regulation enhances the expression of genes associated with bioenergetic pathways, including oxidative phosphorylation, mitochondrial biogenesis, glycolysis, and glutamine utilization, thereby supporting resistance to exhaustion and sustained effector function. Collectively, these data support PRGN-3008 as a clinically translatable, scalable, and controllable CAR T with the potential to expand access to cell therapy across oncology and autoimmune indications.
    DOI:  https://doi.org/10.1126/sciadv.aej2663
  20. Biochem Pharmacol. 2026 Nov 11. pii: S0006-2952(26)00956-1. [Epub ahead of print] 118613
      Regulatory T cells (Tregs) contribute to immune homeostasis and can modulate neuroinflammatory responses, although their functional states differ across central nervous system (CNS) disorders. Forkhead box O1 (FoxO1) is an experimentally established regulator of Treg suppressive function, transcriptional identity, and inflammatory restraint. Genetic studies demonstrate that Treg-specific FoxO1 deficiency disrupts immune regulation and permits aberrant inflammatory gene expression, while PI3K-Akt signaling controls FoxO1 phosphorylation and nuclear localization. These findings provide a mechanistic foundation for investigating FoxO1-dependent Treg dysfunction in neuroinflammation. However, the complete sequence linking inflammatory cytokines, sustained Akt activation, FoxO1 nuclear exclusion, ex-Treg conversion, and neuronal injury has not been demonstrated as a unified causal pathway in human CNS lesions. Evidence from experimental autoimmune encephalomyelitis and other preclinical models supports the therapeutic potential of antigen-directed Treg approaches, while early clinical studies of adoptive Treg therapies in autoimmune disease and transplantation establish a broader translational foundation for Treg-based immunomodulation. We therefore examine FoxO1 as a candidate therapeutic regulator whose modulation may improve Treg stability, rather than as a clinically validated CNS target. Pharmacological preservation of FoxO1 activity and genetic engineering approaches, including phosphorylation-resistant FoxO1 variants, warrant further investigation through direct functional and disease-relevant validation.
    Keywords:  Akt signaling; FoxO1; Neurodegeneration; Neuroinflammation; Regulatory T cells; Treg plasticity
    DOI:  https://doi.org/10.1016/j.bcp.2026.118613
  21. BMC Med. 2026 Aug 03. pii: 629. [Epub ahead of print]24(1):
       BACKGROUND: Glioblastoma, the most common and aggressive primary brain malignancy, remains a lethal disease with limited therapeutic progress despite multimodal treatment. Although chimeric antigen receptor (CAR) T-cell therapy has shown promise in several solid tumors, its broader application in glioblastoma is limited by manufacturing hurdles of autologous T cells and the lack of validated tumor-specific antigens. As an alternative, gamma-delta (γδ) T cells have emerged as an attractive cellular platform, offering MHC-independent tumor recognition, robust ex vivo expansion, and suitability for allogeneic use. However, studies applying CAR engineering to γδ T cells in glioblastoma are extremely limited, and an optimal target antigen has not been clearly defined. In this context, our study identified B7-H3 as a clinically relevant target and demonstrated that B7-H3 CAR γδ T cells exhibited superior antitumor efficacy compared to unmodified γδ T cells across patient-derived and orthotopic glioblastoma models.
    METHODS: To identify an optimal antigen for γδ CAR-T therapy in glioblastoma, we compared the expression and clinical relevance of HER2, GD2, and B7-H3 through analyses of transcriptomic datasets and patient tumor samples. Based on this, human γδ T cells from healthy donors were expanded ex vivo, engineered with a B7-H3-specific CAR, and evaluated for antitumor activity across patient-derived glioblastoma cell lines, organoids, and orthotopic xenograft models.
    RESULTS: B7-H3 was identified as the most clinically relevant antigen, showing high expression in glioblastoma and correlated with poor prognosis and immunosuppressive gene signatures. B7-H3 CAR γδ T cells demonstrated potent cytotoxicity and enhanced cytokine production in B7-H3-high patient-derived glioblastoma models. In patient-derived organoids, CAR γδ T cells significantly reduced tumor viability and invasion. In orthotopic xenografts, a single intracranial administration induced tumor control and prolonged survival, with long-term survivors observed only in the CAR γδ T cell treated group. Across all preclinical models, B7-H3 CAR γδ T cells exerted superior antitumor efficacy compared with parental γδ T cells.
    CONCLUSIONS: These findings suggest B7-H3 as a clinically meaningful and therapeutically targetable antigen in glioblastoma and demonstrate the potent preclinical efficacy of allogeneic B7-H3 CAR γδ T cells, supporting their development as a novel immunotherapeutic strategy for glioblastoma.
    Keywords:  B7-H3; Chimeric Antigen Receptor (CAR); Glioblastoma; adoptive immunotherapy; γδ T cells
    DOI:  https://doi.org/10.1186/s12916-026-05121-2
  22. Mol Ther Adv. 2026 Dec 10. 34(4): 201865
      Chimeric antigen receptor (CAR) T cell therapy has achieved durable and complete responses in a substantial proportion of patients with B cell malignancies. However, during CAR-T cell therapy, the occurrence of adverse events-including on-target/off-tumor toxicity against healthy tissues, cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and the risk of T cell malignancies arising from random genomic integration of viral vectors-significantly threatens patient safety. In this study, we developed a novel truncated HER2 (tHER2)-herpes simplex virus thymidine kinase (HSVTK) dual-switch safety system and site-specifically integrated it into the PDCD1 locus using a Cas12a/adeno-associated virus (AAV)-mediated delivery platform. Importantly, this dual-switch system enables efficient magnetic bead-based enrichment of tHER2-HSVTK (tHER2-TK)-positive T cells, allows tunable modulation of engineered T cell persistence through Herceptin or the small-molecule drug ganciclovir (GCV), and also provides a highly effective purification method before infusion. Collectively, these features enhance safety without compromising therapeutic efficacy, facilitating the development of safer and more controllable engineered T cell immunotherapies.
    Keywords:  T cell immunotherapy; enrichment; safety-controllable; suicide switch; tHER2-TK
    DOI:  https://doi.org/10.1016/j.omta.2026.201865
  23. Front Immunol. 2026 ;17 1987098
      Severe asthma is increasingly managed with endotype-guided biologics, yet a clinically important subgroup remains corticosteroid-dependent, repeatedly exacerbating, or unable to achieve durable multidomain remission. Chimeric antigen receptor (CAR)-engineered cells offer a qualitatively different therapeutic logic: recognition of a cellular compartment can be coupled to selective depletion, localized regulation, or payload delivery, potentially enabling finite immune reprogramming rather than continuous mediator blockade. This Review asks under what conditions that added biological risk could be justified in asthma. We classify evidence into four proximity tiers-direct asthma preclinical evidence, patient-derived ex vivo or disease-adjacent preclinical evidence, human clinical evidence in other immune-mediated diseases, and broader platform evidence-and use this hierarchy to support explicit go/no-go judgments rather than catalogue constructs. Direct asthma studies support lung-directed CAR-regulatory T cells, IL-5/IL-5Rα-directed cytotoxic strategies, multifunctional type 2 pathway control, and allergen-specific CAR-Tregs; clinical efficacy in asthma has not been established. We propose a target-function-patient framework organized around four mandatory gates: clinical necessity, mechanistic coherence, targetability, and reversibility planning. Targets should be prioritized by pathogenic necessity and physiological dispensability; the cellular chassis and receptor program should be chosen according to the required biological function; and treatment should be restricted to biomarker-defined patients whose residual disease burden justifies living-cell therapy. In asthma, maximal cytotoxicity and indefinite persistence are not default virtues. The most plausible initial role is a narrow, biologic-refractory population in whom a controllable, mechanistically verified intervention can durably interrupt a disease-maintaining cellular circuit while preserving host defense and tissue repair.
    Keywords:  CAR-T; CAR-Treg; asthma; chimeric antigen receptor; eosinophils; immune tolerance; precision immunotherapy
    DOI:  https://doi.org/10.3389/fimmu.2026.1987098
  24. J Control Release. 2026 Nov 07. pii: S0168-3659(26)00937-5. [Epub ahead of print]400(Pt B): 115533
      Chimeric antigen receptor (CAR)-T cell therapy faces a critical clinical hurdle: cytokine release syndrome (CRS). Current CRS management strategies have limited selectivity and may interfere with CAR-T cell antitumor activity, highlighting the need for more targeted and precisely controllable interventions. Nanoengineering offers a promising approach to address these limitations by enabling the spatiotemporally controlled monitoring and modulation of inflammatory responses, with the potential to mitigate excessive cytokine release while preserving CAR-T cell therapeutic efficacy, driving a paradigm shift toward programmable, proactive immune regulation. This review systematically examines nanointervention strategies for mitigating CAR-T-induced CRS, including molecular monitoring, cytokine clearance, targeted delivery, stimulus-responsive systems, biomimetic designs, and genetic reprogramming. These approaches enable precise intervention across multiple stages-from early inflammation detection and localized neutralization to source-level cellular engineering. Finally, we discuss challenges in biosafety, clinical translation, and the potential of artificial intelligence-driven predictive platforms. Nanotechnology offers a transformative pathway to redefine CRS from an unpredictable complication into a manageable therapeutic window, paving the way for safer next-generation cellular immunotherapies.
    Keywords:  Chimeric antigen receptor T (CAR-T) cells; Cytokine release syndrome; Immunomodulation; Nanoengineering; Smart response systems
    DOI:  https://doi.org/10.1016/j.jconrel.2026.115533
  25. Int J Mol Sci. 2026 Oct 27. pii: 9607. [Epub ahead of print]27(21):
      Dendritic cells (DCs) are specialized antigen-presenting cells that shape antitumor immunity by integrating antigen uptake, processing, presentation, co-stimulation, and cytokine-mediated T-cell instruction. Their function is therefore critical for generating tumor-specific T-cell responses and may influence responsiveness to immune checkpoint inhibitors. Although early ex vivo DC vaccines established feasibility, safety, and immunogenicity, clinical efficacy has been heterogeneous. Sipuleucel-T demonstrated an overall-survival benefit in metastatic castration-resistant prostate cancer, whereas DCVax-L produced encouraging but methodologically debated survival signals in glioblastoma. More recently, individualized neoantigen mRNA vaccination combined with pembrolizumab has shown durable recurrence-free survival benefit in resected high-risk melanoma. This review examines the biological rationale for DC-directed immunotherapy, tumor-induced DC dysfunction, next-generation DC platforms, in vivo DC targeting, DC-derived extracellular vesicles, negative and controversial clinical evidence, and rational combinations with checkpoint blockade and tumor-microenvironment-modulating strategies. The field is evolving from the use of DCs as cellular vaccine vehicles toward programmable immune-priming approaches that integrate antigen quality, DC functional state, spatial organization, and tumor microenvironment features.
    Keywords:  DC vaccines; FLT3L; antigen presentation; cDC1; cancer immunotherapy; dendritic cells; immune checkpoint blockade; mRNA vaccine; neoantigen vaccine; tumor microenvironment
    DOI:  https://doi.org/10.3390/ijms27219607
  26. Inflamm Bowel Dis. 2026 Nov 10. pii: izag233. [Epub ahead of print]
      Despite major therapeutic advances, inflammatory bowel disease (IBD) remains incurable, and many patients experience primary non-response, secondary loss of response, progressive bowel damage, or lifelong dependence on immunomodulatory therapy. Cellular immunotherapies offer the possibility of moving beyond chronic immune suppression toward durable immune reprogramming. Earlier approaches in IBD, including hematopoietic stem cell transplantation, mesenchymal stem cells, and regulatory T-cell-based therapies, have provided important proof-of-concept but have been limited by toxicity, inconsistent efficacy, local rather than systemic effects, or unresolved manufacturing and durability challenges. Chimeric antigen receptor (CAR) T-cell therapy represents the next-generation strategy that combines potent immune remodeling with antigen-specific targeting. Initially developed for hematological malignancies, CAR T cells have recently shown striking efficacy in refractory autoimmune diseases, particularly through CD19-mediated depletion of B-lineage cells and induction of drug-free remission. In ulcerative colitis, renewed interest in B cells has been driven by evidence of plasmablast expansion, IgG-skewed humoral responses, anti-integrin αvβ6 autoantibodies, and the limitations of conventional anti-CD20 depletion. The first reported case of multidrug-resistant ulcerative colitis treated with CD19 CAR T cells demonstrated rapid clinical, biochemical, endoscopic, and histological remission, providing proof-of-concept for deep B-cell targeting in IBD. However, major uncertainties remain, including long-term durability, relapse after B-cell reconstitution, safety, cost, feasibility, and the risk of CAR T-associated gastrointestinal toxicity. Prospective trials with mechanistic mucosal monitoring are now needed to define the therapeutic potential and appropriate positioning of CAR-based strategies in IBD.
    Keywords:  CAR T-cell; cell therapy; cellular immunotherapy; chimeric antigen receptor T cells; inflammatory bowel disease
    DOI:  https://doi.org/10.1093/ibd/izag233
  27. Front Immunol. 2026 ;17 1909464
      Despite the transformative activity of immune checkpoint blockade (ICB) and adoptive cellular therapies in selected malignancies, durable responses remain limited in many solid tumors, in part because tumor-intrinsic and microenvironmental epigenetic programs can restrict immune recognition and antitumor effector function. Enhancer of zeste homolog 2 (EZH2), a catalytic subunit of polycomb repressive complex 2 (PRC2), contributes to this regulation through canonical H3K27 trimethylation-dependent repression, as well as context-dependent functions that extend beyond a simple model of uniform immune suppression. We organize the available evidence into a dual-axis framework in which tumor-intrinsic EZH2/PRC2 activity can regulate major histocompatibility complex class I and II antigen presentation, interferon and viral-mimicry programs, programmed death-ligand 1 (PD-L1), and T helper 1 (TH1)-type chemokines, whereas tumor-extrinsic EZH2 activity influences macrophages, regulatory T cells, CD8+ T cells, and natural killer (NK) cells. Importantly, these effects are not uniformly immunostimulatory: systemic or prolonged EZH2 perturbation has also been associated with myeloid-derived suppressor cell (MDSC) expansion in selected preclinical settings. Early-phase human studies established the feasibility, but not the incremental clinical benefit, of combining tazemetostat with programmed cell death protein 1 (PD-1)/PD-L1 blockade or chimeric antigen receptor (CAR) T-cell therapy; its subsequent withdrawal after a hematologic safety signal leaves further clinical testing of this strategy to other EZH2- or EZH1/EZH2-directed agents. These observations support mechanism-matched, biomarker-informed, compartment-aware, and temporally controlled EZH2 modulation rather than indiscriminate systemic EZH2 inhibition as the more appropriate framework for future immunotherapy combinations.
    Keywords:  CAR T-cell therapy; EZH2; adoptive cell therapies; immune checkpoint blockade; tumor-intrinsic invisibility
    DOI:  https://doi.org/10.3389/fimmu.2026.1909464
  28. Therapie. 2026 Oct 23. pii: S0040-5957(26)00147-2. [Epub ahead of print]
       AIMS: Cases of secondary cancers (SC) associated with Chimeric Antigen Receptor (CAR) T cell therapy have been reported in the literature prompting safety alerts from both the Food and Drug Administration and the European Medicines Agency after reports of T-cell lymphomas. Establishing causality between CAR-T therapy and SC in patients previously heavily treated for a hematological malignancy is challenging. To clarify this risk, we evaluated SC cases reported to Regional Pharmacovigilance Centers in France for patients with hematological malignancy treated with one of the six authorized CAR-T therapies.
    METHODS: A query in the French Pharmacovigilance Database conducted on 01/24/2025 identified 20 SC cases with a suspected CAR-T specialty, representing 19 patients.
    RESULTS: Most patients were male (63%), with a mean age of 65.2±6 years. Of these, 79% had received CAR-T treatment for B-cell lymphoma and 21% for myeloma. Only 3 of the currently available CAR-T therapies were reported as suspected drugs: tisagenlecleucel, axicabtagene ciloleucel and idecabtagene vicleucel. The mean interval between CAR-T administration and SC diagnosis was 11 months (median of 9.5 months). Of the 20 SC, 11 were secondary hemopathies (6 acute myeloid leukemias, 4 myelodysplasias, and one cutaneous T-cell lymphoma with CAR-T cells detected in the blood and skin). The remaining 9 cases were secondary solid tumors including 3 skin neoplasms, 2 colon adenocarcinomas, one breast cancer, one relapse of oral squamous cell cancer, one jejunal leiomyosarcoma, one manubrial bone sarcoma (the latter two in the same patient). Most patients had established risk factors for these cancers, making CAR-T causality difficult to assess, except for the cutaneous T-cell lymphoma.
    CONCLUSION: Continuous long-term monitoring is essential to further evaluate the benefit-risk profile of CAR-T therapies, especially in settings with poor prognosis.
    Keywords:  Adverse drug reaction; Chimeric antigen receptor T; Pharmacovigilance; Secondary cancer
    DOI:  https://doi.org/10.1016/j.therap.2026.10.006
  29. bioRxiv. 2026 Oct 21. pii: 2026.10.15.759372. [Epub ahead of print]
      Despite its promise in treating B cell malignancies, chimeric antigen receptor (CAR) T cell therapy remains limited by resistance mechanisms that impair CAR T cell stemness, persistence, and effector function. Here, we identified PRDM1 , which encodes the transcriptional repressor, BLIMP-1, as a crucial regulator of CAR T cell terminal differentiation and exhaustion. PRDM1 was highly enriched in exhausted-like tumor-infiltrating CAR T cells from lymphoma patients and in pre-infusion products from clinical non-responders. These findings link increased PRDM1 expression to CAR T cell dysfunction and poor clinical outcomes. Genetic deletion of PRDM1 significantly promoted CAR T cell proliferative capacity, memory differentiation and antitumor efficacy in both hematologic and solid tumor models. Mechanistically, PRDM1 deletion increased the activity of PGC1α, a transcriptional coactivator central to mitochondrial biogenesis and antioxidant capacity, thereby improving mitochondrial function, oxidative stress resistance, and metabolic reserve. Depletion of PGC1α attenuated the improved efficacy of PRDM1 -deficient CAR T cells, indicating an essential role for this pathway downstream of PRDM1 loss. Pharmacologic activation of the PPAR-PGC1α program with a clinically approved agonist, bezafibrate, enhanced CAR T cell antitumor activity without direct tumoricidal effects. Notably, transient exposure to bezafibrate during CAR T cell manufacturing was sufficient to confer durable treatment benefits. Together, our study defines a PRDM1 - PGC1Α axis that controls CAR T cell differentiation, mitochondrial fitness and therapeutic response, which provides a mechanistic and translational framework for advancing CAR T cell therapy across distinct tumor contexts.
    DOI:  https://doi.org/10.64898/2026.10.15.759372
  30. Mol Med. 2026 Aug 03. pii: 216. [Epub ahead of print]32(1):
      Digestive autoimmune diseases impose an escalating global burden, largely because current therapies predominantly target downstream inflammation rather than primordial defects in immune tolerance. The thymus establishes central tolerance through stringent T cell selection and thymus-derived regulatory T cell (tTreg) generation. This review proposes the Thymus-Gut Axis as a working conceptual framework for a dynamic, bidirectional communication network, departing from the traditional unidirectional thymocentric model, while explicitly acknowledging that much of the supporting evidence remains indirect, model-dependent, or derived from broader thymus-microbiota studies rather than from human digestive autoimmunity. We elucidate how thymic dysfunction-driven by defective negative selection, impaired tTreg generation, and AIRE/FEZF2-mediated antigen presentation defects-precipitates the escape of autoreactive clones that drive specific digestive autoimmunity. Conversely, we highlight the hypothetical retrograde signaling arm, wherein gut-derived microbial metabolites, inflammatory cytokines, and migratory dendritic cells have been shown, primarily in murine models, to modulate the thymic microenvironment. However, direct validation in human digestive autoimmunity is currently lacking, and the translational relevance of these findings remains uncertain. Furthermore, sex steroids and early-life microbiota critically program central tolerance, shaping sex-biased susceptibility and lifelong immune homeostasis. Translating these mechanistic insights, we evaluate thymectomy as a clinical model, emerging thymic rejuvenation strategies, and antigen-specific therapeutic Treg therapies. Ultimately, we emphasize the urgent need for human thymic profiling and longitudinal clinical studies integrating systemic thymic output biomarkers with mucosal immune phenotyping to bridge translational gaps and explore speculative but mechanistically rational therapeutic strategies.
    Keywords:  AIRE/FEZF2; Central tolerance; Digestive autoimmunity; Gut microbiota; Thymus-Gut axis; tTreg
    DOI:  https://doi.org/10.1186/s10020-026-01588-0
  31. Clin Exp Med. 2026 Aug 18. pii: 377. [Epub ahead of print]26(1):
      Acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by clonal expansion of immature lymphoid precursors in the bone marrow and extramedullary sites. Although frontline chemotherapy induces remission in most patients, relapse, treatment resistance, and cumulative toxicities remain major challenges. Targeted therapies, including antibody-based agents and tyrosine kinase inhibitors, improve outcomes in selected patients but are limited by cost, durability, and accessibility. Consequently, cell-based interventions, particularly hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor (CAR)-based immunotherapies, have emerged as critical strategies for relapsed or refractory ALL. Although CD19-directed CAR-T cell therapy demonstrates remarkable potential to induce durable remissions, cytokine release syndrome, neurotoxicity, antigen escape, high manufacturing costs, and limited scalability remain significant challenges. Emerging CAR-based approaches, including CAR-NK and other engineered immune cells, along with dendritic cell-based vaccines, represent complementary strategies to enhance safety and efficacy. This review highlights current cell-based therapies for ALL and approaches to improve safety, persistence, and clinical outcomes.
    Keywords:  Acute lymphoblastic leukemia; Adoptive cell therapy; CAR-NK cells; CAR-T cells; Cell-based Therapy; Relapse/refractory ALL
    DOI:  https://doi.org/10.1007/s10238-026-02291-4
  32. Medicine (Baltimore). 2026 Oct 30. 105(44): e51342
       BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) has shown clinical efficacy in hematological malignancies and is being explored for application in breast cancer. However, although the literature in this field is growing rapidly, there is still a lack of systematic bibliometric review of its disease-specific knowledge structure, research hotspots and development trends.
    METHODS: We retrieved literature on CAR-T therapy for breast cancer published between 2012 and 2025 in the Web of Science Core Collection. Bibliometric tools such as CiteSpace were used to perform bibliometric and visual analyses across multiple dimensions, including publication volume, journals, authors, institutions and countries, keywords, subject categories, and co-citations of references.
    RESULTS: The annual number of related publications shows a sustained increasing trend. Harvard University and its affiliated hospitals rank first globally in terms of both the number of published papers and their centrality. "chimeric antigen receptors" and "adoptive immunotherapy" hold a core position. The cutting-edge topics cover the progress and targeted treatments of triple-negative breast cancer. The reference co-citation analysis yielded 53 clusters, covering topics such as solid tumors, antitumor efficacy and tumor microenvironment, reflecting the knowledge base in this field.
    CONCLUSIONS: This study depicts the research pattern and evolution trend of CAR-T therapy in the field of breast cancer. The research focus has shifted from early feasibility exploration to directions such as tumor microenvironment, heterogeneity of target antigens, and combination therapy. Future research can focus on cross-institutional collaboration, expansion of target points, and optimization of CAR structure.
    Keywords:  CAR-T; CiteSpace; bibliometric analysis; breast cancer; immunotherapy
    DOI:  https://doi.org/10.1097/MD.0000000000051342
  33. EBioMedicine. 2026 Nov 09. pii: S2352-3964(26)00424-X. [Epub ahead of print]134 106540
      Cellular senescence acts as a core driver of chronic diseases and tissue degeneration. Conventional small-molecule senolytics face critical limitations including poor target specificity and off-target toxicity when eliminating heterogeneous senescent cell populations. This review systematically discusses senescence-targeted engineered chimeric antigen receptor (CAR)-T immunotherapy, which achieves targeted clearance of pathological senescent cells by recognising specific surface markers. It summarises target-antigen evaluation frameworks, analyzes aged immunosuppressive microenvironment barriers and corresponding engineering strategies, and outlines composite efficacy assessment systems and tiered biomarker-monitoring workflows. Key translational bottlenecks such as imperfect antigen specificity and immune escape are also addressed. Preclinical studies verify organ function restoration and healthspan extension, while clinical evidence remains limited. Future integration of CAR-T technology with smart nanocarriers, synthetic biology and artificial intelligence will promote its clinical translation for senescence-associated disorders.
    Keywords:  CAR-T-cell therapy; Engineered senolytic immunotherapy; Fibrosis treatment; Immune microenvironment; Senescence biomarkers; Senescent cell heterogeneity
    DOI:  https://doi.org/10.1016/j.ebiom.2026.106540
  34. Front Immunol. 2026 ;17 1872123
      RNA technology, most prominently messenger RNA (mRNA), has transformed vaccine development by enabling rapid, sequence-specific antigen design, scalable manufacturing, and transient protein expression. Its long-term significance, however, extends beyond prophylactic vaccination. This Perspective argues that mRNA should be conceptualised as a programmable therapeutic platform capable of integrating vaccination, immune modulation, and on-demand disease treatment. Current mRNA vaccines deliver predefined antigenic instructions, whereas emerging RNA systems, including self-amplifying RNA (saRNA), circular RNA, sequence-engineered mRNA, and targeted lipid nanoparticles (LNPs), may support more adaptable therapeutic functions. Such platforms could prime immunity, replace deficient proteins, encode antibodies, reprogramme immune cells, or induce antigen-specific tolerance. The concept of self-adaptive RNA-based therapeutics remains at an early stage and should not be overstated; most existing systems are programmable at the design stage rather than biologically autonomous after administration. Nonetheless, this conceptual position is no longer purely speculative: the first regulatory approval of a self-amplifying RNA vaccine and controlled-trial evidence of clinical benefit from a personalised neoantigen mRNA therapeutic in resected melanoma indicate that programmable RNA platforms are beginning to move from concept to clinical validation across both the prophylactic and therapeutic ends of the spectrum. Key challenges include tissue-specific delivery, expression control, innate immune activation, repeat dosing, safety assessment, regulatory classification, and equitable access. A self-adaptive RNA-based framework does not replace existing vaccines or biologics but extends them towards responsive, personalised, and temporally controlled therapy.
    Keywords:  RNA-based nanomedicine; cancer vaccines; lipid nanoparticles; mRNA therapeutics; personalised medicine; self-amplifying RNA; synthetic biology; vaccines
    DOI:  https://doi.org/10.3389/fimmu.2026.1872123
  35. Value Health. 2026 Nov 13. pii: S1098-3015(26)05830-4. [Epub ahead of print]
       BACKGROUND: Health care decision making bodies such as regulators and health technology assessment (HTA) agencies have increasingly issued guidance on the use of real-world evidence (RWE). However, it is unclear if current guidance supports the use of 'advanced' causal analytics, characterised here by explicit causal estimands, and flexible assumption-lean modelling (for example, doubly robust approaches and nonparametric methods). Correct application of statistical estimators can help developers avoid statistical model mis-specification bias while achieving greater precision.
    METHODS: We undertook a focused review of publicly available RWE guidance and frameworks from international HTA and regulatory bodies, that included recommendations on causal inference, considering (1) articulation of causal questions and estimands; (2) clear separation of identification assumptions from estimation choices; (3) recommendations to support selection of estimation approaches; (4) expectations for diagnostic checks; and (5) whether and how available causal frameworks are used to organise guidance.
    RESULTS: Guidance primarily emphasises methods to account for confounding bias with limited direction on more granular elements around estimator selection. For example, there is uneven treatment of doubly robust estimation methods which may be endorsed in principle, yet often without sufficient discussion of approaches and practical diagnostics. Causal frameworks are mostly referenced but rarely used to structure guidance, which may have more focus on procedural or reporting elements. Estimand frameworks were frequently referenced in guidance.
    CONCLUSIONS: Strengthening guidance may encourage the application of advanced causal analytics. However, challenges related to the implementation and transparency of these approaches will require upskilling efforts, practical checklists and explainable analytical pipelines.
    Keywords:  HTA; Real-world evidence; Regulators; causal inference; policy review
    DOI:  https://doi.org/10.1016/j.jval.2026.10.014
  36. bioRxiv. 2026 Oct 16. pii: 2026.10.15.759215. [Epub ahead of print]
      Local tumor therapies rarely induce systemic immunity capable of controlling metastatic disease. Here, we engineer an mRNA lipid nanoparticle (LNP) platform to coordinate innate immune sensing and T cell activation in situ through co-delivery of an autoactivated cyclic GMP-AMP synthase mutant (cGAS R241E ) and membrane-tethered IL-12 (IL-12TM). cGAS R241E mRNA LNPs autonomously generated cyclic GMP-AMP in vivo , activating host STING signaling and initiating antitumor responses. Co-administration with IL-12TM mRNA LNPs promoted localized cytokine production, reduced regulatory T cells, and restored effector function in tumor-infiltrating T cells. This combination elicited systemic antitumor immunity and suppressed distal tumors across multiple mouse models. The therapeutic efficacy required CD8 + T cells and IFN-γ signaling in host, supporting a model in which innate DNA sensing is coupled to IL-12-mediated T cell functional reinforcement. In addition, the combination enhanced responsiveness to PD-L1 blockade. Together, these findings establish a clinically translatable strategy to integrate cGAS-STING activation with cytokine-driven T cell programming to drive systemic tumor control.
    DOI:  https://doi.org/10.64898/2026.10.15.759215
  37. Mol Ther. 2026 Sep 01. pii: S1525-0016(26)00680-5. [Epub ahead of print]
      Diffuse large B cell lymphoma (DLBCL) remains a therapeutic challenge due to antigen escape and T cell exhaustion following anti-CD19 chimeric antigen receptor (CAR) T cell therapy. Here, we identify leukocyte immunoglobulin-like receptor-B1 (LILRB1) as a clinically actionable CAR-T target. LILRB1 is widely enriched in nodal and extranodal DLBCL patient samples but exhibits minimal expression on early hematopoietic stem/progenitor cells, offering a favorable therapeutic index. LILRB1 CAR-T cells demonstrated potent, antigen-dependent cytotoxicity against CD19-resistant tumors and mediated durable tumor clearance in xenograft models. To mitigate antigen heterogeneity, we generated LILRB1×CD19 tandem CAR-T cells, which significantly enhanced tumor control. However, long-term therapeutic durability was bounded by progressive T cell exhaustion, characterized by the upregulation of TIM3 and 2B4. To overcome this intracellular bottleneck, we evaluated pharmacologic blockade of nuclear receptor 4A1/2 (NR4A1/2) using the small-molecule ligand 1,1-bis(3'-indolyl) -(3,5-dichlorophenyl) methane (DIM-3,5-Cl2). DIM-3,5-Cl2 successfully reversed CAR-T cell exhaustion, restored polyfunctional cytokine release in vitro, and maximized tumor control and overall survival in stringent in vivo rechallenge models across both LILRB1 and CD19 CAR platforms. Together, these findings establish LILRB1 as a structurally stable CAR target and validate NR4A pharmacotherapy as a generalizable platform adjuvant to optimize adoptive immunotherapies.
    Keywords:  CAR-T cell therapy; LILRB1; NR4A; T cell exhaustion; antigen escape; diffuse large B cell lymphoma
    DOI:  https://doi.org/10.1016/j.ymthe.2026.07.057
  38. J Transl Med. 2026 Aug 14. pii: 1413. [Epub ahead of print]24(1):
       BACKGROUND: Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in B-cell malignancies, but treatment response and immune-related toxicities remain heterogeneous. We characterized peri-infusion gut microbiome dynamics and examined their associations with subsequent response and toxicity.
    METHODS: We performed shotgun metagenomic sequencing of 103 fecal samples from 21 patients with B-cell lymphoma collected on days -7, 0, 7, 14 and 28 relative to CAR-T infusion. We assessed pre-infusion stability, longitudinal microbiome remodeling, and associations with treatment response, cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Longitudinal data were analyzed using mixed-effects models, and composition-aware sensitivity analyses incorporated centered log-ratio transformation and false-discovery-rate correction. Day -7 clinical and microbial features were also evaluated using exploratory nested cross-validation for response and CRS.
    RESULTS: The gut microbiome remained broadly stable at the community level before infusion but underwent early, patient-specific remodeling after CAR-T therapy, characterized by a transient decline in alpha diversity and increased within-patient compositional deviation from baseline. Against this dynamic background, pre-infusion microbial variation was associated with subsequent clinical outcomes. Responders differed from non-responders in baseline microbial diversity, community structure and selected Sutterella and Segatella taxa. Patients who developed CRS showed lower microbial diversity and distinct community composition, whereas no comparable association was detected for ICANS. Exploratory nested cross-validation yielded AUCs of 0.51, 0.55 and 0.72 for the clinical, microbiome and combined response models, respectively, and 0.44, 0.85 and 0.83 for the corresponding CRS models.
    CONCLUSIONS: CAR-T therapy was accompanied by early, patient-specific gut microbiome remodeling, while pre-infusion microbial variation was associated with subsequent treatment response and CRS occurrence. These hypothesis-generating findings require confirmation in larger, independent prospective cohorts.
    Keywords:  B-cell lymphoma; CAR-T therapy; Gut microbiome; Metagenomics
    DOI:  https://doi.org/10.1186/s12967-026-08814-7
  39. Mol Biol Rep. 2026 Nov 12. pii: 1967. [Epub ahead of print]53(1):
      Myocardial infarction (MI) alters the cardiac immune microenvironment through tissue injury, antigen release, and recruitment of innate and adaptive immune cells. Major histocompatibility complex (MHC)-restricted antigen presentation can connect these events to T-cell responses that influence repair or persistent inflammation. This narrative review examines antigen acquisition, initial T-cell priming in cardiac-draining lymph nodes, and subsequent recognition of peptide-MHC complexes within injured myocardium. We integrate these processes with T-cell receptor (TCR) repertoire studies and a spatial framework encompassing the infarct core, border zone, and remote myocardium. Direct experimental evidence for cardiac antigen-specific responses is distinguished from human repertoire associations, findings in other diseases, and proposed mechanisms. In particular, TCR clonal expansion alone does not establish cardiac antigen specificity, and cardiomyocyte antigen display should be separated from professional antigen-presenting cell function. We also consider vascular and lymphatic remodeling, macrophage heterogeneity, and the effects of sex and age. Therapeutic approaches are evaluated by intervention, model, measured outcome, and evidence context, with particular attention to the cardiac risks of immune checkpoint blockade. This framework identifies the experiments needed to connect antigen identity and clonotype function to ventricular remodeling and to assess selective immune interventions after MI.
    Keywords:  Cardiac microenvironment; Clonal T cells; Immune reprogramming; Immunotherapy; MHC-restricted antigen presentation; Myocardial infarction
    DOI:  https://doi.org/10.1007/s11033-026-13173-z
  40. Front Oncol. 2026 ;16 1900851
       Background: The high cost of commercial CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy for relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) is prohibitive for many centres and families worldwide. It is imperative to develop a cost-effective, high-quality local manufacturing system to make CAR-T a financially feasible point-of-care (POC) production option for patients.
    Objective and study design: This was a single-centre, open-label, non-randomised phase II clinical trial aimed at evaluating the efficacy and safety of the locally manufactured autologous anti-CD19 CAR-T cells, generated using the CliniMACS Prodigy system, in the treatment of relapsed/refractory B-ALL. The production efficiency, efficacy, and toxicity of CAR-T therapy were evaluated.
    Results: A total of 6 patients were recruited, including 3 male and 3 female patients. Five patients were recruited upon first relapse, while one was recruited upon second relapse. Two patients had central nervous system involvement upon relapse, as determined by flow cytometry (CNS2). The median age at CAR-T infusion was 9 years (range 4-14 years). The median time from the most recent relapse to CAR-T infusion was 5.33 months (range 4.58-5.83 months). The median percentage of blasts was 5% (range 3%-93%) in bone marrow before CAR-T infusion. All patients received intravenous cyclophosphamide 1,000 mg/m2 and fludarabine 120 mg/m2 for lymphodepletion. The median cell dose was 2.67 × 106 CAR-positive viable T cells/kg (range 2.3-2.95 × 106/kg). The median transduction efficiency was 42.86% (range 33.89%-62.1%) and the median viability of CD3+ cells was 96.22% (range 95.61%-96.78%). The median viral copy number was 2.03 (range 1.72-2.48). All products were intact with no visible damage or leakage. The median filled volume per bag was 28.96 mL (range 15.8-64.01), with a median number of viable CAR-T cells of 76 × 106 cells (range 47 to 174 × 106 cells) and a median concentration of viable CAR-T cells of 2.71 × 106/mL (range 2.41-2.99 × 106/mL). No aggregates or endotoxins (<0.500 EU/mL) were detected in any of the products. Tests for bacterial growth and mycoplasma by quantitative PCR (qPCR) were all negative. Five patients experienced grade 1 cytokine release syndrome (CRS), while one patient experienced grade 3 CRS. CRS occurred at a median of 1.5 days (range 0-6 days) after infusion and resolved by a median of 6.5 days (range 5-16 days) after infusion with the use of a median of 3 doses (range 1-8 doses) of tocilizumab. At a median follow-up of 9 months, all patients remained in remission. The median progression-free survival was not reached. All patients were administered intravenous immunoglobulin replacement every 4 weeks after CAR-T infusion.
    Conclusion: Locally manufactured POC CAR-T may be a feasible option for providing potentially safe, timely, and cost-effective therapy for B-ALL upon first relapse, based on preliminary Hong Kong data from a small number of patients. Further validation in larger studies is recommended to validate scalability, long-term persistence, and cost-effectiveness.
    Keywords:  B-cell; CD19; adoptive therapy; chimeric antigen; immunotherapy; leukaemia; point-of-care systems; receptors
    DOI:  https://doi.org/10.3389/fonc.2026.1900851
  41. Int J Nanomedicine. 2026 ;21 645776
      Cancer vaccines have emerged as a promising immunotherapeutic strategy for inducing durable and tumour-specific immune responses; however, their clinical efficacy remains limited by poor antigen immunogenicity, inefficient delivery, tumor heterogeneity, and the highly immunosuppressive tumor microenvironment (TME). Recent advances in nanotechnology have expanded opportunities for the rational engineering of multifunctional nanoparticle (NP) platforms that can protect therapeutic cargo, enhance antigen presentation and lymphatic transport, co-deliver immunostimulatory adjuvants, and potentially improve immune modulation while reducing systemic exposure. This narrative review provides an overview of next-generation cancer nanovaccines, including lipid-, polymer-, peptide-, inorganic-, biomimetic-, theranostic, in situ-, and stimuli-responsive platforms, with emphasis on their physicochemical design principles, mechanisms of immune activation, and interactions with the TME. Particular attention is given to strategies targeting tumor -associated macrophages, myeloid-derived suppressor cells, regulatory T cells, cancer-associated fibroblasts, and tumor cells to support dendritic-cell maturation, cytotoxic T-cell activation, and anti-tumor immunity. Emerging personalized approaches, including neoantigen- and autologous cell-based nanovaccines, mRNA vaccine platforms, and combinations with immune checkpoint inhibitors, are also discussed. In addition, we examine the growing role of artificial intelligence, machine learning, and computational immunology in neoantigen prioritization, nanoparticle formulation optimization, immunogenicity prediction, and patient-specific vaccine design. Despite encouraging preclinical findings, most cancer nanovaccine platforms remain at the preclinical or early clinical stage, and translation is limited by tumor heterogeneity, variable immune responses, long-term safety and biodistribution concerns, manufacturing reproducibility, scale-up, and regulatory requirements. Overall, the integration of nanotechnology, immunology, precision medicine, and AI offers considerable potential to advance personalized cancer vaccination, but broader clinical validation and standardized manufacturing and evaluation frameworks are required before these platforms can achieve routine clinical application.
    Keywords:  artificial intelligence; cancer immunotherapy; cancer nanovaccines; precision oncology; tumor microenvironment
    DOI:  https://doi.org/10.2147/IJN.S645776
  42. Front Syst Biol. 2026 ;6 1940319
      Cellular senescence causally contributes to age-related and chronic diseases, rendering the targeted immune clearance of pathological senescent cells a promising therapeutic avenue. Progress remains limited by heterogeneity across cell lineages, tissues, inducing stressors, and temporal factors. As antigen expression alone does not ensure immune accessibility, functional recognition, or safety for healthy tissues, these aspects warrant thorough evaluation. A conceptual framework is proposed, distinct from a validated or implementable algorithm, for identifying and prioritizing senescence-associated antigens. This framework requires four criteria that a single candidate antigen must meet within the same cellular context: persistent pathological senescence, immune accessibility via a confirmed surface antigen or naturally presented human leukocyte antigen (HLA) peptide, modality-appropriate functional immune recognition, and exclusion from vital healthy or beneficially senescent states. The mechanistic origin, such as telomere dysfunction, serves as an optional stratification axis that defines coherent subsets rather than a universal prerequisite; data lacking matched telomere and antigen information in the same cells remain unverified. The process distinguishes target nomination from product validation: evidence of recognition in a single modality, such as chimeric antigen receptor (CAR) targeting of a surface antigen, does not confirm validation for alternatives like peptide vaccines. Application of the framework to urokinase-type plasminogen activator receptor (uPAR) and glycoprotein nonmetastatic melanoma protein B (GPNMB) indicates that neither candidate currently meets all criteria, and the telomere axis remains untested for both. Given that multivalent vaccination elicits immunity against each component independently, combining candidates that fail individual criteria risks amplifying liabilities rather than ensuring intersectional specificity. This outcome would require an engineered AND-gated recognition system, where the capitalized operators AND, OR, and NOT denote Boolean logic gates rather than emphasis. The framework remains in the validation phase. Each criterion receives an ordinal grade, a non-compensatory decision rule, a route-specific ligand-density window that sets the quantitative condition for recognition and healthy-cell sparing, and a predefined seven-compartment counter-screening panel. Recognition architectures are formally compared, and a pre-registered benchmarking study with specified falsification criteria is outlined as the framework's validation test.
    Keywords:  cellular senescence; combinatorial targeting; conceptual framework; evidence appraisal; immune senolysis; immunopeptidomics; seno-antigen; telomere dysfunction
    DOI:  https://doi.org/10.3389/fsysb.2026.1940319
  43. J Clin Med. 2026 Oct 28. pii: 8407. [Epub ahead of print]15(21):
      The success of allogeneic haematopoietic stem cell transplantation is limited by three linked problems: graft-versus-host disease (GVHD), relapse, and infection. Pan-T-cell depletion, introduced in the 1980s, controlled GVHD but at the cost of relapse and impaired immune reconstitution. This trade-off has driven the field toward selective graft engineering, manipulating the donor graft's cellular composition to separate GVHD-causing cells from those responsible for graft-versus-leukaemia (GVL) activity and infection control. This review traces that evolution, from CD34+ selection through αβ/CD19 depletion, naïve (CD45RA+) T-cell depletion, adoptive add-back, and gene-edited donor grafts, evaluated against current in vivo prophylaxis, principally post-transplant cyclophosphamide (PTCy). Selective graft-engineering platforms have achieved low rates of chronic GVHD and non-relapse mortality in defined settings. More recently, TREGZI (developed as Orca-T) received U.S. Food and Drug Administration (FDA) approval in June 2026 for adults with haematological malignancies undergoing matched-donor myeloablative allo-HSCT, following a randomised phase III trial against tacrolimus/methotrexate rather than PTCy. However, evidence for most other platforms remains dominated by single-arm, paediatric, or single-centre series; adult data are sparse, and no randomised trial has directly compared ex vivo graft engineering with optimised PTCy-based prophylaxis. Manufacturing infrastructure, cost, and access further limit adoption relative to established prophylaxis. Randomised trials are needed to determine whether, and for which patients, selective graft engineering offers a survival advantage.
    Keywords:  T-cell depletion; allogeneic haematopoietic stem cell transplantation; graft-versus-host disease; graft-versus-leukaemia; post-transplant cyclophosphamide; precision graft engineering
    DOI:  https://doi.org/10.3390/jcm15218407
  44. J Cancer Educ. 2026 Nov 12.
      Cell-based cancer immunotherapies such as chimeric antigen receptor (CAR) T cell therapy are an established and evolving class of cancer treatment, yet few cancer education curricula give students hands-on experience with the laboratory methods that underlie them. To address this gap, we developed and implemented a novel, small-enrollment curriculum designed to teach upper-level undergraduate and graduate students about immunotherapies and CAR-T cell technology by paralleling a typical bench-scale development process. Students isolated T cells from porcine peripheral blood mononuclear cells (PBMCs) via immunomagnetic selection, followed by flow cytometry to assess purity, viability, and yield. Students then used pre-engineered B7H3 CAR-T cells to perform co-culture assays with U87 glioblastoma cells to evaluate tumor cell killing efficacy. Cytotoxicity was qualitatively evaluated using immunofluorescence microscopy, while IFN-γ release was quantified using enzyme-linked immunosorbent assay (ELISA). Student performance was evaluated through electronic laboratory notebooks, discussion questions, a capstone project, and student-generated data. Our results demonstrate students' high academic performance across assignments and the successful execution of complex laboratory workflows. Collectively, these findings establish the feasibility and implementation of a research-integrated curriculum providing foundational exposure to immuno-oncology research tools and CAR-T cell production techniques.
    DOI:  https://doi.org/10.1007/s13187-026-03011-y
  45. Int J Mol Sci. 2026 Nov 05. pii: 9907. [Epub ahead of print]27(21):
      Cancer immunotherapies, including chimeric antigen receptor (CAR) T-cell therapies, bispecific antibodies (BsAbs), and immune checkpoint inhibitors (ICIs), have improved outcomes across hematologic and solid malignancies. Infection risk remains heterogeneous and depends on treatment platform, target antigen, lymphodepletion, immune reconstitution, concomitant immunosuppression, and supportive care. This narrative review synthesizes clinical trials, observational studies, and guidance identified through PubMed/MEDLINE, reference screening, and a targeted literature update through October 2026. It focuses on infection incidence, microbiological spectrum, antimicrobial resistance (AMR), multidrug-resistant (MDR) colonization and infection, antimicrobial exposure, prevention, and stewardship. Severe infections can be frequent with BCMA-directed BsAbs: the MagnetisMM-3 study reported grade 3-4 infections in 39.8% of elranatamab-treated patients, while a pooled global teclistamab cohort reported grade 3-4 infections in 55.3%; these estimates are study-specific and are influenced in part by COVID-19. Direct AMR evidence is concentrated in CAR-T and broader cellular-therapy cohorts, while comparable data for BsAbs and ICIs remain limited. Associations between broad-spectrum antibiotic exposure, microbiome disruption, and CAR-T outcomes are clinically important but remain vulnerable to confounding. Prevention should integrate immune status, prior microbiology, antimicrobial exposure, and local resistance patterns rather than infer resistance risk from treatment platform alone. Prospective studies using harmonized outcomes are needed to improve individualized infection prevention and antimicrobial stewardship.
    Keywords:  CAR-T cells; antimicrobial resistance; bispecific antibodies; immune checkpoint inhibitors; immunoglobulin replacement; infection prevention; infections; vaccination
    DOI:  https://doi.org/10.3390/ijms27219907
  46. bioRxiv. 2026 Oct 12. pii: 2026.10.10.756030. [Epub ahead of print]
       Background: CAR-T cells have shown limited efficacy against solid tumors, where they face two major challenges: restricted tumor infiltration and sustained intensive engagement that drive them to exhaustion. Conventional CAR design has largely emphasized high-affinity interactions with slow dissociation, further limiting tumor infiltration and exacerbating exhaustion and dysfunction. We hypothesize that most current CARs are kinetically over-stabilized for solid tumors and that a fast-on/fast-off, " cheek-kiss " mode of engagement permits transient CAR-antigen disengagement, thereby facilitating tumor infiltration and preserving CAR-T cell fitness in tumor mass.
    Methods: We identified two monoclonal antibodies targeting the same epitope of epidermal growth factor receptor with comparable k on but distinct k off rates: cetuximab (Cet) and its humanized derivative H1. CAR-T cells incorporating these binders were evaluated in vitro and in vivo . Large, established human tumor xenografts were treated with low-dose CAR-T cells in NSG mice to model conditions of limited T cell availability and sustained tumor antigen exposure.
    Results: Cet and H1 exhibited comparable k on but markedly different k off rates, with H1 displaying fast-off kinetics with approximately 18-fold shorter binding dwell time. As CARs, H1 showed reduced antigen occupancy and less stable tumor-T cell engagement than Cet. Despite comparable in vitro cytotoxicity, H1 CAR-T cells accumulated more efficiently following tumor stimulation. At high doses, both CAR-T cell products eradicated established tumors. Under low-dose conditions, however, H1 CAR-T cells exhibited superior expansion, persistence, tumor infiltration, and antitumor efficacy, whereas Cet CAR-T cells showed limited expansion and only transient tumor control. Cet CAR-T cells progressively downregulated surface CAR expression, increased PD-1 expression, and exhibited reduced tumor infiltration and impaired functional recovery. In contrast, H1 CAR-T cells preserved surface CAR expression, exhibited greater tumor infiltration, maintained a less exhausted, more central memory-like phenotype, and retained effector function.
    Conclusion: Fast-on/fast-off binding kinetics enhance CAR-T tumor infiltration, expansion, persistence, and functional fitness, resulting in improved control of established solid tumors. The data provides a rationale for shifting CAR design from affinity optimization toward kinetic optimization to improve the efficacy and safety of CAR-T therapy for solid tumors.
    WHAT IS ALREADY KNOWN ON THIS TOPIC: CAR design has largely focused on antigen-binding affinity, whereas the contribution of binding kinetics, particularly the dissociation rate, to CAR-T cell function, expansion, persistence, tumor infiltration, and antitumor efficacy remains poorly defined.
    WHAT THIS STUDY ADDS: In this study, we found that, compared with slow-off binding, fast-off kinetics enhance CAR-T cell tumor infiltration, expansion, persistence, and functional fitness in tumor-bearing mice, revealing previously underappreciated effects of antigen-binding kinetics on CAR-T cell tumor infiltration and performance in solid tumors.
    HOW THIS STUDY MIGHT AFFECT RESEARCH PRACTICE OR POLICY: This study provides a rationale for incorporating antigen-binding kinetics into CAR design and optimization. The TCR-inspired fast-on/fast-off antigen engagement may help CAR T cells maintain fitness during sustained antigen exposure and thereby improve their infiltration, persistence, and antitumor activity in solid tumors.
    DOI:  https://doi.org/10.64898/2026.10.10.756030
  47. Curr Res Transl Med. 2026 Nov 06. pii: S2452-3186(26)00054-1. [Epub ahead of print]74(4): 103618
       BACKGROUND: Chimeric antigen receptor T-cell (CAR T-cell) therapy is the standard of care for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The impact of pre-existing chronic obstructive pulmonary disease (COPD) on outcomes of LBCL after CAR-T cell therapy are not well characterized. This study aimed at evaluating the significance of pre-existing COPD on overall survival (OS) in LBCL treated with CAR-T cell therapy.
    METHODS: We conducted propensity score-matched cohort study using registry data from TriNetX Global Collaborative Network. Patients aged ≥18 years who received CAR T-cell therapy were identified using ICD-10-PCS and CPT codes and stratified by the presence (or absence) of documented diagnosis of COPD (ICD-10-CM: J44.x). Propensity score matching was performed adjusting for age, gender, ethnicity, and race. Primary outcome was OS. Secondary endpoints included hematologic and non-hematologic toxicities.
    RESULTS: A total of 173 patients with COPD and 173 without COPD were included. Cohorts were balanced across most baseline characteristics. Axicabtagene ciloleucel was the most commonly administered product in both cohorts. The COPD cohort demonstrated significantly worse median OS (760 vs. 1412 days). The 5-year OS was higher in patients without COPD (HR=0.72 (95%CI=0.52-0.99), p = 0.048).
    CONCLUSIONS: COPD is associated with inferior OS following CAR T-cell therapy in R/R LBCL. These results advocate for the integration of COPD status into pre-CAR T-cell risk stratification protocols and for proactive pulmonary optimization, multidisciplinary evaluation, and heightened vigilance in this cohort. Patients with R/R LBCL and concurrent COPD should not be categorically excluded from CAR T-cell therapy.
    Keywords:  Chimeric antigen receptor T-cell therapy; Chronic obstructive pulmonary disease; Large B-cell non-hodgkin lymphoma; Overall survival
    DOI:  https://doi.org/10.1016/j.retram.2026.103618
  48. Curr Opin Neurol. 2026 Dec 01. 39(6): 571-577
       PURPOSE OF REVIEW: Immunotherapy has transformed the treatment of many malignancies but has not yet produced comparable improvements in survival for patients with gliomas. This review examines the biological rationale for immunotherapy across molecularly defined gliomas, lessons from unsuccessful immune checkpoint inhibitor trials, and emerging strategies including vaccines, adoptive cellular therapies, bispecific T-cell engagers, immunocytokines, innate immune modulators, oncolytic viruses, and approaches to improve delivery within the central nervous system.
    RECENT FINDINGS: Randomized studies have established that programmed death-1 (PD-1) blockade alone is insufficient for unselected patients with glioblastoma. Treatment resistance reflects multiple interacting barriers, including low and heterogeneous antigen expression, limited T-cell infiltration, T-cell dysfunction, immunosuppressive myeloid populations, corticosteroid exposure, and treatment-associated lymphopenia. Importantly, these features differ across glioma subtypes. Recent studies demonstrate that vaccines directed against clonal IDH1 and H3K27M mutations can generate durable antigen-specific immunity, while locoregionally delivered chimeric antigen receptor T (CAR-T) cells targeting IL13Rα2, EGFR/EGFRvIII, GD2, and B7-H3 can produce rapid and occasionally durable tumor regression. Oncolytic viruses and immunocytokines provide complementary approaches to remodeling the glioma microenvironment.
    SUMMARY: The principal challenge in glioma immunotherapy is no longer demonstrating that immune cells can recognize and kill glioma cells but converting immune recognition into durable tumor control. Future progress will likely depend on matching therapy to molecular subtype, targeting multiple or clonal antigens, optimizing immune-cell trafficking and persistence, modifying the suppressive microenvironment, and longitudinally monitoring tumor and immune evolution.
    Keywords:  bispecific T-cell engager; cancer vaccine; chimeric antigen receptor T cell; glioblastoma; glioma; immune checkpoint inhibition; immunotherapy; oncolytic virus
    DOI:  https://doi.org/10.1097/WCO.0000000000001524
  49. Clin Exp Vaccine Res. 2026 Oct;15(4): 229-247
      Biomimetic nanoparticles (BMNPs) have emerged as promising platforms for cancer vaccines and immunotherapy by combining nanoscale delivery systems with biological interfaces derived from cells or extracellular vesicles (EVs). Their therapeutic behavior is influenced by the biological source, surface composition, nanoparticle architecture, and incorporated cargo, which together determine cellular recognition, antigen processing, immune activation, and tissue targeting. This review discusses major BMNP platforms, including cancer-cell, immune-cell, red blood cell, platelet, and EV-derived systems, using a structure-to-function perspective. The mechanisms underlying antigen delivery, dendritic cell activation, T-cell priming, immune checkpoint regulation, and tumor microenvironment modulation are examined, alongside representative preclinical evidence in cancer vaccination, combination immunotherapy, and emerging infectious disease vaccination. Key barriers to clinical translation, including biological heterogeneity, manufacturing reproducibility, quality control, potency, safety, and regulatory characterization, are also considered. Emerging approaches involving precision membrane engineering, standardized manufacturing, computational design, and personalized biomimetic vaccines are further discussed. Overall, BMNPs provide a versatile link between biological recognition and nanomedicine, but clinical translation will require reproducible structure-function relationships, rigorous characterization, and stronger preclinical validation.
    Keywords:  Antigen presentation; Biomimetic materials; Cancer vaccines; Immunotherapy; Nanoparticles
    DOI:  https://doi.org/10.7774/cevr.2026.15.e23
  50. Cancers (Basel). 2026 Nov 03. pii: 3527. [Epub ahead of print]18(21):
      Cutaneous T-cell lymphoma (CTCL) is a malignancy of skin-homing T cells associated with increased risk of second malignancies. CAR-T lymphoma is a mature T-cell malignancy arising in cancer patients treated with chimeric antigen receptor T-cell (CAR-T) therapy. Because of its frequent cutaneous involvement, CAR-T lymphoma can mimic CTCL, which in turn can resemble cutaneous sequelae of oncologic therapies. Careful evaluation of these entities in cancer patients is therefore essential, yet little guidance exists regarding optimal methods of screening, diagnosis, and treatment. Clinicians managing CTCL in cancer patients should consider how oncologic treatment toxicities may overlap with CTCL treatment toxicities or affect patients' risk for other skin cancers. Where possible, immune-boosting or at least immune-preserving treatments are preferred, with immune checkpoint inhibition emerging as an important option in selected patients. Patients with a history of CAR-T therapy and new, persistent skin findings should undergo careful work-up with molecular screening for lymphoproliferative processes. Presence of a CAR in lesional tissue can be suggestive but is not diagnostic of a CAR-T-associated malignancy. Treatment for any patient with a cutaneous T-cell or CAR-T lymphoma and a second cancer should be an interdisciplinary effort tailored to the patient's specific medical history and molecular profile. Further research is needed to establish better evidence-based guidelines for treatment of these patient populations.
    Keywords:  CAR-T; CTCL; lymphoma; malignancy; screening
    DOI:  https://doi.org/10.3390/cancers18213527
  51. Pharm Stat. 2026 Nov-Dec;25(6):pii: e70149. [Epub ahead of print]25(6):
      The US Food and Drug Administration (FDA) released a landmark draft guidance in January 2026 entitled 'Use of Bayesian Methodology in Clinical Trials of Drug and Biological Products' (Food and Drug Administration 2026)-the first comprehensive regulatory framework for Bayesian primary inference in drug and biologic trials. This Viewpoint critically appraises the Guidance across four dimensions: (1) The regulatory and philosophical tensions in Section IV.A.1, 'Calibration to Type-I Error Rate', with specific improvement recommendations; (2) the Bayesian borrowing framework articulated in Sections III and V, including gaps in dynamic borrowing and effective sample size (ESS) interpretation; (3) the Guidance's synergy with FDA's Project Optimus and the companion dose-optimisation guidance (August 2024) (Food and Drug Administration 2024), and how Bayesian methods underpin the optimal biological dose (OBD) paradigm; and (4) the limited operational detail in Section III.F for efficacy-toxicity joint models and seamless Phase I/II designs-the design class most capable of OBD identification. It is contended that the Guidance is a historic advance, yet its oncology dose-finding section devotes most of its operational detail to maximum tolerated dose (MTD)-oriented designs. A regulatory taxonomy of Bayesian dose-finding designs and targeted improvements for the final guidance are proposed. The appraisal refers to the nonbinding January 2026 draft text, which may change before finalisation.
    Keywords:  Bayesian borrowing; Bayesian methodology; FDA draft guidance; Type‐I error calibration; project optimus
    DOI:  https://doi.org/10.1002/pst.70149
  52. Front Immunol. 2026 ;17 1984200
      Recent research reveals that microproteins encoded by non-canonical open reading frames (ncORFs) substantially enrich the cancer immunopeptidome, driven by oncogenic stress, essential cellular functions, immune tolerance mechanisms, and antigen-processing biases. These microproteins, often critical for tumour survival, produce peptides presented on tumour cell surfaces, offering shared antigen targets for immunotherapy, particularly in tumours with low mutational burden. Here we integrate multi-level evidence demonstrating how translational reprogramming under stress, essentiality constraints limiting antigen loss, and selective antigen processing converge to promote ncORF-derived peptide presentation. While emerging data suggest immunogenicity of some microproteins, clinical validation remains pending. Advancing therapeutic applications requires development of specialised computational predictors, rigorous immunopeptidomics workflows, and prospective thymic peptide profiling to ensure efficacy and safety. This framework highlights ncORF-derived microproteins as promising yet complex targets, expanding the landscape of cancer immunotherapy beyond canonical neoantigens.
    Keywords:  cancer immunotherapy; immunopeptidomics; microproteins; non-canonical open reading frames (ncORFs); tumour antigens
    DOI:  https://doi.org/10.3389/fimmu.2026.1984200
  53. RSC Adv. 2026 Nov 09.
      Viruses are no longer used merely as naturally occurring tools for gene transfer or as blunt cytolytic agents. Researchers are rewriting their genomes, capsids, tropisms, regulatory elements, and payloads to create therapeutic systems that sense disease, execute conditional programs, and remodel pathological tissue. In oncology, engineered oncolytic viruses (OVs) can combine tumor-selective replication with immunogenic cell death, antigen release, and local immune stimulation. In parallel, viral-vector engineering, particularly AAV and LVs, is addressing central limitations of gene delivery: the prevalence of pre-existing neutralizing antibodies, the difficulty of systemic administration and repeat dosing (AAV), and the manufacturing bottleneck of ex vivo cell therapies (LV). The clinical record is encouraging but uneven: T-VEC has shown that an engineered herpes simplex virus can improve durable responses in selected melanoma lesions, while G47Δ/teserpaturev and newer armed HSV platforms provide evidence of feasibility, safety, and occasional durable responses in difficult solid tumors. Lentiviral vector-based in vivo CAR-T cell generation, exemplified by KLN-1010/inMMyCAR and related first-in-human programs, signals a paradigm shift away from ex vivo manufacturing. However, the broader field has not converted its large preclinical literature into a proportional number of clinically meaningful, systemically deployable medicines. The main bottlenecks remain delivery, tumor heterogeneity, immune clearance, suboptimal pharmacodynamic biomarkers, manufacturing complexity, resistance, and the difficulty of proving benefit for products with delayed or immunologically mediated effects. This review examines the synthetic biology toolkit for programmable viral therapeutics through a unified engineering framework that integrates OVs, AAV, and LVs by design principle rather than by vector class. We discuss tumor-selective promoters, microRNA detargeting, retargeted capsids and ligands, attenuation, genome-scale assembly, immune-stimulatory payloads, bispecific and trispecific engagers, logic-gated circuits, safety switches, serodivergent AAV capsids, biomimetic cloaking, cell carriers, biomaterial delivery systems, and in vivo CAR-T generation. Our central thesis is that the next generation of viral medicines will be selected not by the most elaborate genome, but by the most coherent alignment of five measurable success factors: tumor selectivity, immune remodeling, delivery and biodistribution, controllable safety, and manufacturability. The emerging paradigm is therefore programmable viral therapeutics: context-sensitive biological medicines designed to operate within the constraints of human tumors and human immunity.
    DOI:  https://doi.org/10.1039/d6ra09938f
  54. Transl Oncol. 2026 Nov 07. pii: S1936-5233(26)00433-X. [Epub ahead of print]75 103097
      Although immune checkpoint inhibitors have revolutionized cancer treatment, therapeutic resistance and heterogeneous patient responses remain major clinical challenges. Current paradigms predominantly focus on amplifying effector T cells (Teffs); however, this approach frequently encounters structural bottlenecks imposed by a tumor-locked, suppressive immune homeostasis. Central to this aberrant equilibrium are regulatory T cells (Tregs), which persistently elevate immune activation thresholds and restrict durable antitumor responses. In this review, we propose a paradigm shift toward reshaping baseline T cell homeostasis, highlighting exercise as a potent, systemic physiological intervention. Regular exercise systematically counteracts tumor-induced homeostatic locking by reprogramming immune metabolism, attenuating chronic inflammation, and improving tissue perfusion. Rather than indiscriminately depleting Tregs, exercise dynamically recalibrates the Teff/Treg balance, lowering activation thresholds while preserving systemic immune tolerance. Furthermore, we propose that structured physical activity may support a form of "homeostatic memory," with potential implications for the durability of immunotherapy responses. Integrating exercise into oncological care offers a translational, host-centered strategy to optimize the immune background, thereby unlocking the full clinical potential of cancer immunotherapy.
    Keywords:  Cancer immunity; Exercise intervention; Immune regulation; T cell homeostasis; Translational medicine; Treatment tolerance
    DOI:  https://doi.org/10.1016/j.tranon.2026.103097
  55. BMC Med Res Methodol. 2026 Aug 18. pii: 245. [Epub ahead of print]26(1):
       BACKGROUND: The increasing volume of scientific manuscripts has strained traditional peer-review systems, prompting interest in artificial intelligence (AI) as a potential solution. However, the comparative performance of large language models (LLMs) in critically appraising oncological research remains unexplored.
    METHODS: We conducted a cross-sectional study evaluating the peer-review capabilities of three LLMs-Claude Sonnet 4.5, Google Gemini 3.0 Thinking, and OpenAI ChatGPT 5.1-using 50 blinded landmark oncology trials identified from ASCO, ESMO, and NCCN guidelines. Manuscripts were anonymized by removing identifying information and submitted to each model with a standardized prompt. Two investigators independently analyzed reviews for final verdicts, trial awareness, journal suitability assessments, and concerns across five domains (biological, methodological, statistical, trial groups, and reporting). Chi-square tests with Bonferroni correction and logistic regression were used for statistical analysis.
    RESULTS: Significant differences were observed in reviewer verdicts among models (p < 0.001). Claude Sonnet 4.5 was most stringent (74% major revisions, 6% rejections), while Google Gemini 3.0 was most lenient (58% minor revisions, 4% acceptances). Trial awareness varied significantly (Claude 54%, Gemini 50%, ChatGPT 14%; p < 0.001). Methodological concerns differed among models (Claude 86%, ChatGPT 80%, Gemini 62%; p = 0.014). Logistic regression identified statistical concerns as the only significant predictor of critical verdicts (OR = 8.57; 95% CI 1.28-57.4; p = 0.027). Journal suitability was assessed by Claude in 90% of reviews but by Gemini in none.
    CONCLUSION: LLMs demonstrate heterogeneous performance in peer-reviewing landmark oncology trials, with significant variation in stringency, trial recognition, and methodological scrutiny. These findings highlight the need for standardized frameworks before integrating AI into peer-review processes.
    Keywords:  Artificial Intelligence; Clinical Trials as Topic; Medical Oncology; Natural Language Processing; Peer Review, Research; Publishing
    DOI:  https://doi.org/10.1186/s12874-026-02978-y
  56. Cancer Discov. 2026 Nov 12. OF1
      Chimeric antigen receptor T-cell therapies for brain tumors have shown limited durability, in part because of an antibody attack on the engineered receptor itself, new research shows. Suppressing that response, either with preconditioning drugs or by redesigning the chimeric antigen receptor, helps make the cells and their therapeutic benefit last.
    DOI:  https://doi.org/10.1158/2159-8290.CD-NW2026-0106
  57. Front Pharmacol. 2026 ;17 1980237
      Novel anticancer therapies have transformed oncology but have also expanded the spectrum of cancer therapy-related cardiovascular toxicity, including myocarditis, ventricular dysfunction, hypertension, vascular inflammation, thrombosis, arrhythmias, fibrosis, and heart failure. In cardio-oncology, the cardio-immune microenvironment provides a useful framework for integrating cardiovascular toxicity across immune checkpoint inhibitors, CAR-T cell therapy and other T-cell-redirecting therapies, HER2-directed therapies, VEGF/VEGFR inhibitors, antibody-drug conjugates, radiotherapy-containing regimens, and combination treatments. This Review discusses the cardio- immune microenvironment as a tissue-level network in which immune cells, cardiomyocytes, endothelial cells, vascular cells, fibroblasts, soluble mediators, and extracellular-matrix cues interact during injury and repair. Rather than proposing a universal immune origin for all cardiotoxic effects, we distinguish three routes by which novel anticancer treatments may enter this network: immune initiation, systemic inflammatory translation, and primary cardiomyocyte, endothelial, vascular, or payload-related injury followed by immune amplification and remodeling. We define mechanistically meaningful convergence as engagement of a shared downstream cellular-molecular response module by therapies with distinct proximal mechanisms, while distinguishing such convergence from nonspecific injury-repair responses. We organize the cardio-immune framework around five mechanistic domains: immune tolerance breakdown, cytokine-driven systemic inflammation, sterile danger sensing, myeloid and stromal reprogramming, and endothelial-immune coupling. We further discuss how these mechanisms may inform therapy-specific risk stratification, biomarker interpretation, imaging surveillance, mechanism-guided intervention, and multi-omics approaches in precision cardio-oncology. This context-dependent framework may help clarify why distinct anticancer therapies can produce overlapping cardiovascular phenotypes while preserving therapy-specific mechanisms and clinical management priorities.
    Keywords:  CAR-T-cell therapy; antibody–drug conjugates; cancer therapy–related cardiovascular toxicity; cardio-immune microenvironment; cardio-oncology; endothelial dysfunction; immune checkpoint inhibitors
    DOI:  https://doi.org/10.3389/fphar.2026.1980237
  58. Int J Nanomedicine. 2026 ;21 649666
      Gynecological cancers, including ovarian, cervical, and endometrial cancers, remain major contributors to female morbidity and mortality worldwide. Conventional treatments-surgery, chemotherapy, and radiotherapy-have improved outcomes, but advanced or recurrent disease is still associated with poor prognosis, chemoresistance, and tumor heterogeneity. Immunotherapy has emerged as a transformative strategy because of its specificity and potential for durable responses. However, the immunosuppressive tumor microenvironment and inefficient delivery of immunotherapeutic agents limit clinical benefit. Nanocarriers, including organic, inorganic, and biomimetic platforms, can improve targeted delivery, sustained release, biocompatibility, and tumor microenvironment remodeling, thereby enhancing immunotherapy. This review summarizes major immunotherapeutic modalities for gynecological cancers-immune checkpoint blockade, CAR-T cell therapy, tumor vaccines, and oncolytic viruses-and the classification and characteristics of commonly used nanocarriers. We focus on nanocarrier-mediated immunotherapeutic mechanisms in ovarian, cervical, and endometrial cancers, and further highlight emerging lipid nanoparticle/mRNA and programmable RNA delivery strategies. Finally, we analyze challenges in clinical translation and provide perspectives for future development, aiming to support fundamental research and clinical application of nano-immunotherapy in gynecological malignancies.
    Keywords:  clinical translation; gynecological cancers; immunotherapy; lipid nanoparticles; mRNA vaccines; nanocarriers; targeted delivery
    DOI:  https://doi.org/10.2147/IJN.S649666
  59. Gene Ther. 2026 Nov 10.
    Expert Committee on the Annual Congress of the Chinese Society for Cell & Gene Therapy, the Chinese Society for Cell Biology
      Cell and gene therapy (CGT) represents a paradigm shift in medicine, offering immense potential to correct inherited genetic defects and provide healthy or empowered cells for therapy, thereby revolutionizing the treatment of cancers, chronic diseases, and hereditary diseases. Against a backdrop of rapid technological advancements and accelerating commercialization in the field, the 5th China Annual Congress on Cell and Gene Therapy was held in Haikou, Hainan, from November 20 to 22, 2025. At the congress, 175 speakers from around the world gave presentations on immune cell therapeutics, gene therapy, stem cell-based regenerative medicine, and regulatory frameworks alongside industrialization. These presentations highlighted that immune cell therapies are expanding beyond hematologic malignancies into solid tumors and autoimmune diseases. Concurrently, gene therapy has demonstrated promising clinical efficacy in treating genetic disorders alongside the evolution of therapeutic tools, while stem cell-based regenerative medicine has advanced both in fundamental research and in clinical translation for tissue repair. The congress also addressed the current status and challenges of China's regulatory system and industrialization landscape. Although the preliminary clinical outcomes of most reported CGT therapies are encouraging, long-term efficacy and safety require further observation. Furthermore, critical challenges remain, including the absence of harmonized potency assays and interoperable real-world evidence systems, manufacturing scalability and cost barriers, and the need for further refinement of the regulatory framework to accommodate rapid technological evolution. This report summarizes the key advancements and outstanding issues discussed at the congress, aiming to facilitate the sustainable and robust development of the CGT field.
    DOI:  https://doi.org/10.1038/s41434-026-00657-7
  60. Transl Cancer Res. 2026 Oct 30. 15(10): 767
       Background: Regulatory T cells (Tregs) play a critical role in shaping the immunosuppressive tumor microenvironment in gastric cancer and have attracted increasing attention in the context of immunotherapy. This study aimed to provide a comprehensive bibliometric overview of global research on Tregs in gastric cancer from 2005 to 2025 and to identify evolving thematic trends.
    Methods: Publications were retrieved from the Web of Science Core Collection using a predefined search strategy. A total of 464 English-language publications, including articles and reviews, were included. Bibliometric analyses were performed using the bibliometrix R package, VOSviewer, and CiteSpace to assess publication trends, country and institutional productivity, collaboration patterns, keyword co-occurrence, and citation bursts. The 50 most-cited publications were further analyzed to identify high-impact thematic focuses.
    Results: Annual publication output demonstrated a sustained increase over the past two decades, with notable growth after 2015. China contributed the highest number of publications, Japan showed the highest citation impact per article, and the United States occupied a central position in international collaboration networks. Keyword clustering identified three major research themes: Treg biology and prognosis, immunotherapy-related research, and Helicobacter pylori-associated immunomodulation. Temporal and citation-burst analyses revealed an increasing emphasis on immune checkpoint blockade and translational immunotherapy in recent years.
    Conclusions: This bibliometric study systematically characterizes the global research landscape of Tregs in gastric cancer and highlights a progressive shift from mechanistic and prognostic studies toward immunotherapy-oriented and translational research. The findings also identify key future priorities, including standardized characterization of Treg subsets, validation of Treg-related biomarkers, and integration of spatial and multi-omics approaches with patient-level clinical outcomes.
    Keywords:  Gastric cancer; Helicobacter pylori (H. pylori); bibliometric analysis; immunotherapy; regulatory T cells (Tregs)
    DOI:  https://doi.org/10.21037/tcr-2026-0878
  61. Transl Cancer Res. 2026 Oct 30. 15(10): 789
       Background and Objective: Messenger RNA (mRNA) vaccines now encompass licensed respiratory vaccines, a self-amplifying ribonucleic acid (RNA) product, and individualized cancer immunotherapies in late-stage development. The expansion of the field has made platform-level comparisons increasingly important because efficacy, tolerability, manufacturability, and tissue targeting are influenced by the RNA architecture as well as by the delivery system. This narrative review examines molecular engineering, delivery, emerging RNA architectures, infectious-disease translation, and cancer immunotherapy, with emphasis on developments reported through 2026.
    Methods: Targeted literature searches were conducted in PubMed through 31 August 2026, complemented by reference chaining and targeted searches of official regulatory sources. English-language mechanistic studies, clinical trials, regulatory documents, and focused reviews were prioritized. Particular attention was given to evidence published from 2023 to 2026 on self-amplifying RNA (saRNA), circular RNA (circRNA), molecular optimization, and individualized neoantigen vaccines.
    Key Content and Findings: Nucleoside-modified non-replicating mRNA formulated in lipid nanoparticles remains the most clinically validated architecture. Molecular optimization now extends beyond nucleoside substitution to cap chemistry, untranslated-region selection, coding-sequence and RNA-structure design, poly(A) control, and removal of double-stranded RNA (dsRNA) impurities. saRNA has reached regulatory authorization and offers dose-sparing potential, whereas circRNA remains predominantly preclinical and still faces unresolved manufacturing and quality-control questions. Infectious-disease programs have established reusable capabilities in antigen design, lipid nanoparticle formulation, manufacturing, and regulatory comparability. In oncology, intismeran autogene plus pembrolizumab has produced durable recurrence-free survival (RFS) benefit in resected melanoma, while pancreatic-cancer studies of autogene cevumeran show that vaccine-induced T cell responses vary substantially between patients. Tumor clonality, neoantigen quality, antigen presentation, the immune microenvironment, treatment setting, and manufacturing time are therefore as important as the number of encoded mutations. Artificial intelligence (AI) can improve neoantigen ranking but does not remove the need for biological validation.
    Conclusions: No RNA architecture is uniformly superior across indications. Further clinical progress will depend on matching transcript design and delivery to the intended immune response, improving predictive antigen selection and patient stratification, and transferring validated manufacturing and regulatory capabilities from infectious-disease vaccines to individualized oncology without assuming that platform maturity alone is sufficient for antitumor efficacy.
    Keywords:  Messenger RNA vaccine (mRNA vaccine); circular RNA (circRNA); lipid nanoparticle; neoantigen immunotherapy; self-amplifying RNA (saRNA)
    DOI:  https://doi.org/10.21037/tcr-2026-1598
  62. Front Immunol. 2026 ;17 2001812
      Immune-checkpoint blockade has improved outcomes in triple-negative breast cancer (TNBC), but resistance remains common. Natural killer (NK) cells provide complementary surveillance when classical major histocompatibility complex class I (MHC-I) expression is lost or heterogeneous. HLA-E can inhibit NK cells and subsets of CD8+ T cells through CD94/NKG2A, but can also engage activating CD94/NKG2C. In breast cancer, HLA-E associations depend on classical MHC-I status, while spatial TNBC studies link MHC-I heterogeneity to NKG2A-mediated resistance in experimental models. Evidence varies by subtype and remains predominantly translational; clinical efficacy of NKG2A blockade has not been established, including in the small MIMOSA trial of HER2-positive disease. This Mini Review evaluates breast cancer-specific and cross-tumor evidence, the NKG2A/NKG2C balance, therapeutic combinations, and practical biomarker development. We propose prospective assessment of tumor-cell surface HLA-E, regional MHC-I status, NKG2A-positive effectors, activating-receptor balance, and spatial proximity rather than HLA-E positivity alone.
    Keywords:  HLA-E; NKG2A; breast cancer; immune checkpoint; immunotherapy; monalizumab; natural killer cells; triple-negative breast cancer
    DOI:  https://doi.org/10.3389/fimmu.2026.2001812
  63. J Cancer Prev. 2026 Oct 30. 31(4): 195-213
      Cancer progression is driven by complex interaction among malignant cells, stromal components, and tumor-infiltrating immune cells, which together define the tumor immune microenvironment (TIME). Tumor cells evade immune surveillance by impairing the cytotoxic CD8+ T-cell function and promoting immunosuppressive cell populations including regulatory T cells, tumor-associated macrophages, and myeloid-derived suppressor cells. Although immune checkpoint blockade and adoptive T-cell therapy have advanced cancer treatment, their clinical efficacy remains limited by therapeutic resistance, heterogenous responses, and treatment-related toxicities. Dietary factors have emerged as potential modulators of antitumor immunity through their effects on immune cell metabolism, inflammatory signaling, and the gut microbiota. In this review, we summarize the mechanisms underlying immunosuppression within the TIME and discuss how macronutrients, micronutrients, food-derived bioactive compounds, and dietary patterns regulate immune cell function and antitumor immune responses. We further highlight the potential of dietary modulation to improve immunotherapy outcomes while critically evaluating current preclinical and clinical evidence. Finally, we discuss the challenges associated with translating these findings into clinical practice, including bioavailability, context-dependent effects, and the need for well-designed clinical trials. A better understanding of diet-mediated immune regulation may provide new opportunities for developing complementary strategies to enhance cancer immunotherapy.
    Keywords:  Diet; Gastrointestinal microbiome; Immunotherapy; Metabolism; Tumor immune microenvironment
    DOI:  https://doi.org/10.15430/JCP.26.050
  64. Health Care Sci. 2026 Nov 10.
      Healthcare data remain difficult to use because of fragmentation, sensitivity, and overlapping rights and responsibilities. A virtual digital patient links a longitudinal representation of an individual patient with modeling capabilities for specified clinical or research questions. This article proposes a conceptual socio-technical framework for governing how virtual digital patients are created, accessed, used, and updated. A narrative synthesis of selected policy, modeling, interoperability, and health artificial intelligence literature informs four interdependent layers: data and representation; artificial intelligence modeling and simulation; governance and control; and clinical and external use. The framework connects standardized longitudinal representations, knowledge-supported reasoning, disease-specific simulation, authorization, output review, lifecycle management, and accountability. It distinguishes data resources, model services, operational capabilities, and potentially recognizable assets; technical functionality alone does not establish asset status. An illustrative oncology trial-design scenario shows how purpose-limited requests could produce bounded, reviewed outputs without transferring raw patient records. A staged validation agenda addresses data quality, model performance, workflow safety, clinical utility, and governance controls. The article reports neither a new algorithm nor a deployed or clinically validated system. Its contribution is an integrated reference architecture for evaluating how patient-specific modeling, institutional stewardship, and value return may be aligned. Disease-specific implementation and empirical evaluation are required before clinical or commercial claims can be established.
    Keywords:  accountability; artificial intelligence; data assetization; digital twin; medical data governance; model‐informed drug development; privacy‐preserving computation; virtual digital patient
    DOI:  https://doi.org/10.1002/hcs2.70115
  65. Folia Microbiol (Praha). 2026 Nov 09.
      Immune checkpoint blockade has improved outcomes across several cancers, yet many patients experience primary or acquired resistance. The gut microbiome may contribute to this variation through metabolic activities that influence systemic and tumor-associated immunity. This narrative review examines microbiome-associated metabolites as potential markers of immunotherapy response, with particular attention to their biological origins, immune effects, and clinical validation. We distinguish metabolites produced directly by microorganisms, such as fermentation-derived short-chain fatty acids and bacterial indoles, from host substrates transformed by microbial enzymes, including secondary bile acids. We also consider host-microbial co-metabolites and predominantly host- or tumor-derived mediators, such as kynurenine and CD39/CD73-generated adenosine, whose regulation may be influenced by the microbiome. Evidence concerning inosine, polyamines, and lipid mediators is interpreted according to their specific metabolic sources. These compounds have been linked to epithelial barrier function, antigen presentation, T-cell activity, and immunosuppressive signaling, although their effects vary across biological compartments and clinical settings. We examine the limitations of stool and circulating measurements, pre-analytical variability, metabolomic assays, and the distinction between mechanistic findings and clinically validated associations. Current evidence supports further investigation of selected metabolite signatures, but few have undergone independent clinical validation. Reliable biomarker development will require source-aware interpretation, standardized quantitative methods, longitudinal clinical studies, and evidence that metabolite measurements improve decisions about immunotherapy.
    Keywords:  Analytical standardization; Biomarker validation; Cancer immunotherapy; Clinical metabolomics; Gut microbiome; Immune checkpoint blockade; Immunotherapy resistance; Microbiome-associated metabolites
    DOI:  https://doi.org/10.1007/s12223-026-01634-8
  66. MedComm (2020). 2026 Nov;7(11): e71011
      CRISPR-Cas genome editing represents one of the most transformative advances in modern molecular biology, enabling programmable site-specific genetic modification that has revolutionized functional genomics and precision therapeutic development. Beyond canonical Cas9 nucleases, the CRISPR toolkit has diversified into precision base editors, prime editors, CRISPR-associated transposases, and Cas12/Cas13 RNA-targeting effectors, each with distinct mechanistic properties. Clinically, ex vivo CRISPR therapies for hemoglobinopathies have secured regulatory approval, while base editing, prime editing, and in vivo Chimeric Antigen Receptor (CAR)-T candidates are advancing through trials for a broad spectrum of hematologic, oncologic, and rare genetic disorders. However, existing reviews largely address technical innovation or clinical translation in isolation, lacking a holistic, up-to-date synthesis of the full bench-to-bedside trajectory of CRISPR technology. This review systematically dissects the molecular mechanisms, advantages, and limitations of core CRISPR editing platforms; summarizes pivotal clinical data across hemoglobinopathies, CAR-T immunotherapy, muscular dystrophy, cystic fibrosis, cardiometabolic diseases and rare monogenic diseases; evaluates delivery systems including lipid nanoparticles and viral vectors; and discusses key translational barriers such as off-target genotoxicity and immunogenicity alongside emerging optimization strategies. This work provides a holistic bench-to-bedside framework for CRISPR research, offering critical insights to advance next-generation precision genetic medicine.
    Keywords:  CRISPR delivery; CRISPR‐Cas9; base editing; clinical translation; gene therapy; genome editing; prime editing
    DOI:  https://doi.org/10.1002/mco2.71011
  67. JMIR Med Inform. 2026 Nov 13. 14 e105990
       Unlabelled: The Clinical Data Interchange Standards Consortium (CDISC) has become the cornerstone of regulatory data submission frameworks for pharmaceutical and biotechnology organizations worldwide. Although the US Food and Drug Administration and Japan's Pharmaceuticals and Medical Devices Agency require standardized study data, clinical data teams continue to face persistent operational barriers, including controlled terminology misuse, ambiguity in mapping protocol-specific data to domains, insufficient validation automation, and conformance findings that add review cycles. This Viewpoint argues that sustainable improvement in CDISC submission quality requires organizations to move beyond isolated technical fixes toward a staged, systematically assessable model of implementation maturity and proposes the CDISC Implementation Maturity Model (CIMM) as a framework for that assessment. Technical fixes-domain selection discipline, controlled terminology governance, template-based and metadata-driven automation, and multilayered validation-matter, but organizations that treat them as independent problems tend to underinvest in the institutional structures that make any one fix durable. Adapted from staged capability maturity modeling and established maturity model design procedures, the CIMM characterizes organizational CDISC capability across 5 dimensions-process standardization, automation coverage, terminology governance, validation integration, and institutional knowledge distribution-and 5 maturity levels, from Ad Hoc to Optimizing. Each of the 25 level-dimension cells carries an observable indicator, and an organization's overall maturity is set by its weakest dimension. The framework is offered as a conceptual synthesis; its level definitions and the submission outcomes associated with each level are hypotheses to be tested, not validated findings. Submissions that are efficient to produce and more likely to clear regulatory review on the first attempt are more plausibly reached through the deliberate, staged development of the 5 capability dimensions the CIMM describes than through any single tool or technique. Testing the reliability of CIMM level assignment and its association with observed submission outcomes is the necessary next step.
    Keywords:  ADaM; Analysis Data Model; CDISC; Clinical Data Interchange Standards Consortium; Define.xml; FDA submission; Food and Drug Administration; SDTM; Study Data Tabulation Model; clinical data standards; controlled terminology; implementation maturity model; metadata-driven transformation; regulatory submissions
    DOI:  https://doi.org/10.2196/105990
  68. PLoS One. 2026 ;21(11): e0362221
      Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of B-cell malignancies, but relapse after CD19-directed therapy remains a major challenge, often because of loss or downregulation of CD19 expression. CD22 is an attractive alternative target because it is expressed on malignant B cells, including in many cases of CD19-negative disease. In this study, we generated and characterized novel anti-CD22 monoclonal antibody-derived CAR constructs for in vitro evaluation. Four anti-CD22 monoclonal antibody clones were initially screened, and two clones, 24A7G6 and 29H9C8, were selected for CAR development based on their favorable binding and CAR surface expression profiles. Second-generation CAR constructs containing either a 4-1BB or CD28 costimulatory domain were generated and introduced into primary human T cells. The resulting CAR T cells were evaluated for expansion, immunophenotype, activation and inhibitory marker expression, cytokine secretion, short-term cytotoxicity, long-term co-culture activity, and sequential tumor rechallenge against CD22-positive Raji and Nalm-6 cells and CD22-negative K562 cells. Both 24A7G6- and 29H9C8-derived CAR T cells expanded efficiently, showed predominant CD8 + populations with naïve and central memory phenotypes, and mediated potent antigen-specific cytotoxicity against CD22-positive target cells, while showing no activity against CD22-negative cells. Following antigen stimulation, CAR T cells upregulated activation markers and showed modest increases in inhibitory receptors. In long-term co-culture and sequential rechallenge assays, all constructs retained antitumor activity under prolonged antigen exposure. Notably, the 24A7G6-CD28 CAR demonstrated enhanced sustained tumor control compared with the corresponding 4-1BB construct in extended assays, whereas short-term cytotoxicity was broadly comparable across constructs. These findings show that the newly generated 24A7G6 and 29H9C8 scFvs can function as effective targeting domains for CD22-directed CAR T-cell development and provide an in vitro basis for prioritizing lead constructs for further preclinical evaluation.
    DOI:  https://doi.org/10.1371/journal.pone.0362221
  69. Blood. 2026 Nov 09. pii: blood.2026035207. [Epub ahead of print]
      Chronic lymphocytic leukemia (CLL) remains incurable and autologous T-cell-based therapies induce durable remissions in only a minority of patients. Although poor T-cell performance in CLL has been attributed to exhaustion, T cells from CLL patients retain cytokine production and lack key transcriptional markers of exhaustion, suggesting an alternative state of differentiation. Here, we performed an integrated phenotypic, epigenetic and functional analysis of circulating CD8⁺ T cells from treatment-naive CLL patients to define the nature and therapeutic relevance of terminal differentiation in CLL. CD8⁺ T cells from treatment-naive CLL patients were enriched for a terminally differentiated, CD27⁻CD28⁻CD57⁺KLRG1⁺ population with several senescence-associated features, including increased cell size, granularity, β-galactosidase activity, and reduced basal autophagy. However, these cells lacked key hallmarks of irreversible senescence. Instead, CLL T cells mounted robust but transient proliferative bursts and developed activation-associated γH2AX signals followed by impaired persistence and increased cell death upon repeated activation. Especially CD57⁺ T cells were vulnerable and incompatible with the experimental steps required for CAR T-cell manufacturing. The potent, acute effector function of these cells could, however, be harnessed by bispecific T-cell engagers, which induced effective cytolysis of both cell lines and primary CLL targets by these T cells. Collectively, our data support a model in which CD8+ T-cell dysfunction in CLL reflects accumulation of short-lived, terminally differentiated effector cells rather than canonical exhaustion or irreversible senescence. This state limits durable persistence required for CAR T-cell approached while preserving acute cytotoxicity relevant for bispecific antibody-based therapies in CLL.
    DOI:  https://doi.org/10.1182/blood.2026035207
  70. Acta Ophthalmol. 2026 Nov 14.
      Foundation models are rapidly emerging as a major development in ophthalmic artificial intelligence, largely because they can achieve strong downstream performance with fewer labelled images than conventional supervised models, including those pretrained on natural images, although the size of this advantage varies across tasks. While recent studies have described the architectures and benchmark results of ophthalmic foundation models, less attention has been paid to a more practical question: Once such a model is available, how should a clinician or researcher adapt it to a specific task? This review addresses this question from a practical perspective. We first discuss what ophthalmic foundation models can learn during pretraining and how these learned representations can be transferred across downstream tasks. We then examine the main adaptation strategies that are currently used in practice, with attention to their relative strengths, limitations and data requirements. We also review key methodological considerations that influence whether adaptation is likely to be reliable, including annotation quality, dataset construction, patient-level splitting, external validation, calibration and explainability. The main aim of this review was not to categorize foundation models themselves, but to provide a clinically oriented framework for deciding when fine-tuning is likely to be useful and when simpler alternatives may be sufficient. We argue that this decision should weigh labelled-data availability, disease rarity, domain match between pretraining and target task, model availability and licensing, computational constraints and the need for generalization across devices or populations, none of which alone justifies fine-tuning, and that any adapted model should be compared with a supervised baseline and validated in a manner matched to its intended use. By shifting the focus from model development to model adaptation, this review aimed to support more informed and realistic use of foundation models in ophthalmic clinic and research.
    Keywords:  fine‐tuning; foundation models; ophthalmology; retinal imaging; self‐supervised learning; transfer learning
    DOI:  https://doi.org/10.1111/aos.70276
  71. J Clin Med. 2026 Oct 24. pii: 8287. [Epub ahead of print]15(21):
      Background: Chimeric antigen receptor T-cell (CAR-T) therapy is associated with numerous adverse effects, among which acute kidney injury (AKI) remains poorly characterized. This study aimed to determine the incidence and risk factors of AKI following CAR-T therapy. Methods: This retrospective study was conducted among adult patients who received CAR-T cell therapy at an university hospital between April 2019 and December 2023. The incidence and risk factors for AKI, as well as its impact on overall survival and progression-free survival, were analyzed using univariate and multivariate analyses. Results: A total of 220 patients were included (mean age 63 ± 12 years), mostly treated for B-cell lymphomas. Pre-existing chronic kidney disease (CKD) was present in 26% of patients, and 24% had been admitted to the intensive care unit. The cumulative incidence of AKI was 20.5% (n = 45), occurring early after CAR-T infusion (4 days). Among AKI cases, 22% were KDIGO stage 3, and 15.6% required renal replacement therapy. In multivariate analysis, pre-existing CKD was strongly associated with AKI occurrence (adjusted OR 8.9), as was exposure to ACEI and ARBs with nephrotoxic agents (adjusted OR 2.7). Severity of cytokine release syndrome, and CAR-T-associated encephalopathy were associated with AKI in univariate analysis. Severe AKI was associated with reduced progression-free survival. Conclusions: Acute kidney injury commonly occurs following CAR-T cell therapy, and its occurrence was closely linked to pre-existing renal comorbidities and cumulative exposure to nephrotoxic agents and ACEI and ARBS. The severity of AKI was associated with reduced overall survival and progression-free survival.
    Keywords:  CAR-T cell; CRS; ICANS; acute kidney injury; intensive care unit
    DOI:  https://doi.org/10.3390/jcm15218287
  72. bioRxiv. 2026 Oct 16. pii: 2026.10.09.757975. [Epub ahead of print]
      Dirty mice experiments suggest that laboratory mice fail to model certain human immune responses due to their limited microbial exposure. The identity, nature, and number of microbes required to normalize the immune system are unknown. Through systematic screening, we uncovered unexpected cross-kingdom microbial interactions and identified four enteric microbes spanning viruses, fungi, and protists sufficient to reproduce key immunological features of pet store mice and adult humans. This consortium also altered cancer outcomes, shifting tumorigenesis toward the anatomical pattern of human familial adenomatous polyposis in Apc Min/+ mice and recapitulating the imperfect response of many patients to chimeric antigen receptor (CAR) T cell therapy. Thus, surprisingly few microbes can profoundly reshape immune states and disease responses, providing a tractable approach to naturalize laboratory mouse immunity.
    DOI:  https://doi.org/10.64898/2026.10.09.757975
  73. Drug Resist Updat. 2026 Nov 04. pii: S1368-7646(26)00150-0. [Epub ahead of print]90 101498
      Therapeutic resistance remains a major barrier to durable cancer control despite advances in immunotherapy, targeted therapy, cellular therapies, chemotherapy, and radiotherapy. Although tumor cell-intrinsic genetic and epigenetic alterations are well-established drivers of resistance, treatment outcomes are also shaped by dynamic interactions within the tumor microenvironment (TME). Among its stromal and immune constituents, tumor-associated macrophages (TAMs) are prominent regulators of therapeutic resistance because of their functional plasticity and capacity to integrate diverse environmental signals. Here, we introduce macrophage-centered resistance programs as an integrative framework comprising four recurrent, non-mutually exclusive functional modules: lipid-associated, matrix-remodeling, glyco-immune, and metabolic programs. These modules link tumor-derived stressors to macrophage adaptation, immune suppression, stromal remodeling, and therapeutic persistence, while allowing substantial overlap, context dependence, and dynamic interconversion. We further distinguish associative observations from mechanistic and causal evidence and examine how macrophage-associated resistance mechanisms interact with treatment-specific tumor cell-intrinsic pathways across immune checkpoint blockade, cellular therapy, targeted therapy, chemotherapy, and radiotherapy. Finally, we discuss macrophage-directed therapeutic strategies and the requirements for biomarker-guided precision immunotherapy, including clinical validation, assay standardization, and longitudinal monitoring. This framework is intended as a testable organizational model for understanding macrophage-mediated therapeutic resistance and guiding more precise macrophage-directed interventions.
    Keywords:  Cancer immunotherapy; Macrophage-centered resistance programs; Therapeutic resistance; Tumor microenvironment; Tumor-associated macrophages
    DOI:  https://doi.org/10.1016/j.drup.2026.101498
  74. EJNMMI Res. 2026 Aug 29. pii: 160. [Epub ahead of print]16(1):
       BACKGROUND: Chimeric Antigen Receptor (CAR) T cell therapies for solid tumours face challenges regarding inefficient trafficking to the tumour site, limited extravasation and impaired persistence within an immunosuppressive microenvironment. Non-invasive imaging approaches capable of capturing the dynamic behaviour and biodistribution of CAR T cells are therefore needed to better understand these barriers. This study explores the use of compartmental modelling to interpret technetium-99 m pertechnetate ([99mTc]TcO4-) uptake by CAR T cells co-expressing the sodium iodide symporter (NIS) reporter gene in a prostate cancer NSG mouse model using single-photon emission computed tomography computerised tomography (SPECT/CT).
    RESULTS: Co-expression of hNIS with a prostate-specific membrane antigen (PSMA) targeting CAR did not impair CAR T cell function and enabled non-invasive visualisation of CAR-hNIS T cell infiltration in vivo. Dynamic SPECT/CT imaging revealed clear differences in tumour uptake between CAR-hNIS treated mice and control groups. Compartmental modelling using a reversible two-compartment framework demonstrated increased tracer influx and reduced tracer efflux in CAR-hNIS treated tumours. These kinetic changes indicate that tumour signal arises from NIS-mediated tracer uptake and delayed tracer washout in tumours containing infiltrating CAR T cells, rather than from passive perfusion or non-specific delivery alone. Immunohistochemistry confirmed CAR T cell infiltration in the tumours.
    CONCLUSIONS: This work establishes a proof-of-concept for applying kinetic modelling to interpret CAR T cell infiltration in vivo using dynamic hNIS-based SPECT imaging. By distinguishing tracer delivery from tracer washout kinetics and correcting for variability in tracer bioavailability, this approach provides a more sophisticated biological interpretation of tumour uptake than static imaging alone. These findings highlight the potential of integrating kinetic modelling into future quantitative cell-tracking strategies to improve the evaluation and optimisation of CAR T cell therapies for solid tumours.
    Keywords:  Adoptive cell transfer; Cell tracking; Kinetic modelling; SPECT/CT; Sodium iodide symporter
    DOI:  https://doi.org/10.1186/s13550-026-01492-y
  75. Funct Integr Genomics. 2026 Nov 07. pii: 326. [Epub ahead of print]26(1):
      High-throughput technologies now make it possible to simultaneously generate genomic, transcriptomic, epigenomic, proteomic, and metabolomic data. Spatial and single-cell platforms, in turn, provide cellular and spatial information in greater detail. Relying on a single omics method captures only a fraction of this complexity and often overlooks interactions across different layers. Despite these advances, clinical applications remain limited. This review examines integration strategies, along with their applications in various diseases, and the machine learning methods used to implement them. Rather than focusing solely on predictive performance, the aim is to support biological reasoning by formulating testable hypotheses, drawing causal inferences, and gaining insights that can guide clinical decisions. A reanalysis of a publicly available chronic lymphocytic leukemia dataset revealed that one data type was missing in approximately one-third of patients. When early and intermediate integration were combined with simple zero imputation, agreement dropped to chance and near-chance levels. In contrast, late integration, which does not require data imputation, was largely unaffected by this issue. This demonstrates that findings regarding integration strategies cannot be considered in isolation from how missing data are handled. The review also covers approaches that directly address missing data. Major barriers to clinical application include confounding batch effects, unreliable feature attribution when features are correlated, and deficiencies in clinical quality assurance. This review proposes four criteria to help identify models that not only ensure statistical validity but also genuinely support biological reasoning: mechanistic specificity, causal grounding, failure transparency, and decision relevance.
    Keywords:  Multi-omics integration; artificial intelligence; biological reasoning; machine learning; precision medicine; spatial genomics
    DOI:  https://doi.org/10.1007/s10142-026-02107-4
  76. Int J Technol Assess Health Care. 2026 Nov 09. 42(1): e105
      The Middle East and North Africa (MENA) region faces growing pressure on health systems due to rising burdens of noncommunicable diseases, increasing healthcare costs, and expanding access to innovative health technologies. Health technology assessment (HTA) is increasingly recognized as a critical tool to support transparent and efficient resource allocation; however, HTA institutionalization and capacity vary widely across the region. This Perspective article examines the potential for meaningful regional HTA collaboration, drawing on insights from a panel discussion co-organized by HTAi and the ISPOR UAE Chapter in early 2026, and situating these reflections against the long-standing experience of European HTA cooperation. While acknowledging fundamental structural and governance differences between MENA and the European Union, the article identifies transferable lessons, enabling conditions, and pragmatic entry points for collaboration, such as clinical evidence generation initiatives and early scientific engagement with technology developers. It argues for an incremental, trust-based approach focused on high-value, transferable HTA components aimed at strengthening national HTA systems rather than replacing them.
    Keywords:  European HTA cooperation; European Union Health Technology Assessment; Middle East and North Africa; capacity building; evidence generation; governance; health technology assessment; regional collaboration; scientific information exchange
    DOI:  https://doi.org/10.1017/S0266462326104140
  77. Cancer Discov. 2026 Nov 08. OF1-OF15
      China's oncology drug development ecosystem has shifted from rapid pipeline expansion toward clinical value-driven innovation. We review regulatory reform and the 2015 to 2025 evolution of clinical development across small molecules, mAbs, multispecific antibodies, antibody-drug conjugates, and cell and gene therapies. China's disease burden and enrollment capacity have enabled globally relevant advances in EGFR-mutant lung cancer, gastrointestinal malignancies, hepatocellular carcinoma, nasopharyngeal carcinoma, and CLDN18.2-directed therapies. We highlight persistent challenges in target and modality convergence, biomarker definition, therapeutic window optimization, manufacturing consistency, and globally interpretable evidence generation and discuss how artificial intelligence may connect target discovery, drug design, and clinical trial optimization more efficiently.
    SIGNIFICANCE: China has become a major source of oncology trials and modality innovation, but scale alone will not ensure global impact. This review links regulatory reform, disease-specific opportunity, target biology, therapeutic format, and evidence quality across a decade of solid tumor development. It defines the conditions under which China-originated programs can generate globally practice-changing evidence. See related article by Shi, p. XX .
    DOI:  https://doi.org/10.1158/2159-8290.CD-26-1628
  78. Healthcare (Basel). 2026 Nov 09. pii: 3822. [Epub ahead of print]14(21):
      The European Union medical device sector is analysed in several largely separate strands of the literature: regulatory studies of the Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR), innovation research on individual technology classes, commercial market reporting, and health-policy work on adoption and reimbursement. Integration across these dimensions is limited, so the mechanisms by which regulatory change propagates into innovation, market access and healthcare-system outcomes remain poorly specified. This review addresses that gap by proposing and applying a five-stage conceptual framework: Regulation, Evidence, Innovation, Market Access, and Healthcare-System Impact, and by using it to structure a reproducible literature synthesis. Four bibliographic databases and a defined set of institutional sources were searched for the period January 2017 to June 2026, with a targeted update to October 2026 and the geographical scope restricted to the EU-27 and the European Economic Area (EEA); identified records were screened against explicit criteria, and the retained documents were coded against the five framework dimensions. Search, screening and coding records are reported in full, with the PRISMA flow diagram, checklist, screening log and coded corpus provided. Rather than reporting market values as isolated figures, the synthesis examines relationships between certification duration, evidence intensity, segment growth, market concentration and access conditions. Three findings emerge. First, at the segment level, the association between evidence intensity and growth runs in the opposite direction to the one usually assumed: the segments with the heaviest evidence burden, Class III implantable and Class C/D in vitro diagnostics, grow in the mid-single digits, whereas the fastest-growing segments, digital health and wearables, sit predominantly in lower conformity-assessment classes. Certification duration is nevertheless substantial throughout, with median application-to-certificate totals reported at approximately 17-19 months for in vitro diagnostics and 19-22 months for medical devices, so that evidence requirements act less as a uniform brake on growth than as a selection mechanism determining which firms can participate in the most regulated segments. Second, the innovation consequence of regulatory delay has moved from assertion to estimation: a two-market economic model estimates that introducing a three-year supplementary protection certificate limited to Class III devices would raise EU-directed development effort by 13.46% in a single-market EU calibration, and by 5.6% in the two-market setting and manufacturer survey evidence records a reallocation of first approvals and launches away from the EU. Third, the December 2025 targeted revision of the medical device regulation (MDR) and in vitro diagnostic regulation (IVDR), implementing regulation (EU) 2026/977 setting maximum conformity-assessment timelines, the selection of the first two medical devices for joint clinical assessment in October 2026, and the phased mandatory use of the European database on medical devices (EUDAMED) together constitute a partial correction whose effects are not yet observable. The framework identifies where regulatory change translates into consequences for manufacturers, providers and patients, and shows that the chain is well evidenced at its regulatory origin and weakest at its healthcare-system terminus.
    Keywords:  health technology assessment; healthcare systems; market assessment; medical device regulation; medical devices; regulation–innovation interaction
    DOI:  https://doi.org/10.3390/healthcare14213822
  79. Cytotherapy. 2026 Sep 04. pii: S1465-3249(26)00963-1. [Epub ahead of print]29(1): 103004
      Reproducible and scalable manufacturing is essential for broader clinical implementation of chimeric antigen receptor T cell therapy. We developed a semi-automated, functionally closed manufacturing process for non-viral piggyBac transposon-mediated EPHB4 chimeric antigen receptor T cells and compared it with the conventional manual process. Cryopreserved leukapheresis products were used as starting materials, and recovered PBMCs were allocated to paired manual and semi-automated manufacturing runs. The semi-automated process incorporated closed cell recovery and washing, piggyBac-mediated electroporation, antigen-presenting feeder cell-mediated expansion, rocking-motion bioreactor culture with controlled dissolved oxygen, and functionally closed final harvest. Final products were evaluated for expansion, chimeric antigen receptor expression, T cell composition, memory-associated phenotype, mitochondrial respiration, and repeated tumor-killing activity. The semi-automated process achieved 9.21 ± 3.30-fold expansion, compared with 1.57 ± 1.25-fold expansion in the manual process. Final products generated by the semi-automated process retained chimeric antigen receptor expression (57.2 ± 7.2%), high CD3-positive T cell purity, broadly similar CD4/CD8 composition, and low programmed cell death protein 1 expression. CD45RA-positive/CD62L-positive memory-associated populations were maintained. Semi-automated culture with controlled dissolved oxygen also retained spare respiratory capacity and mitochondrial ATP-generating capacity and maintained serial tumor-killing activity through repeated tumor challenge. These findings demonstrate that semi-automated, functionally closed manufacturing with dissolved oxygen-controlled bioreactor expansion is feasible for piggyBac EPHB4 chimeric antigen receptor T cells and preserves key phenotypic, metabolic, and functional attributes. This process may support further clinical development of non-viral piggyBac transposon-mediated chimeric antigen receptor T cell therapy.
    Keywords:  CAR-T cell therapy; Closed system; Dissolved oxygen; Mitochondrial fitness; PiggyBac transposon; Semi-automated manufacturing
    DOI:  https://doi.org/10.1016/j.jcyt.2026.103004
  80. Molecules. 2026 Nov 03. pii: 3965. [Epub ahead of print]31(21):
      Tumor metabolic reprogramming contributes to an immunosuppressive microenvironment and limits the efficacy of cancer immunotherapy. Natural products can regulate multiple metabolic pathways, but their therapeutic application is often restricted by poor bioavailability and insufficient tumor exposure. Nanomedicine offers a means to overcome these limitations while enabling more selective metabolic intervention. This review examines how natural product nanomedicines remodel tumor immunometabolism and influence antitumor immunity. Current evidence shows that these nanomedicines can regulate glucose and lactate metabolism, lipid and amino acid-associated metabolism, and mitochondrial/redox homeostasis. Such metabolic remodeling has been associated with improved CD8+ T-cell activity, altered immunosuppressive immune populations, induction of immunogenic cell death, and improved responses to immune checkpoint blockade in selected studies. However, causal links between metabolic regulation and immune remodeling remain insufficiently defined, and metabolic interventions may exert distinct effects across tumor and immune cell populations. Future studies should emphasize cell-specific targeting, direct assessment of metabolic target engagement, and pharmacokinetic-pharmacodynamic relationships. Natural product nanomedicines therefore represent a promising platform for integrating metabolic intervention with cancer immunotherapy.
    Keywords:  cancer immunotherapy; metabolic reprogramming; nanomedicine; natural products; tumor immunometabolism
    DOI:  https://doi.org/10.3390/molecules31213965